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Background: Leptin, initially believed to simply be a satiety hormone responsible for 
obesity, is now recognized as a pleiotropic cytokine that is involved in many biological 
processes; including the body’s host inflammatory response. Clinically, leptin may affect 
lung function although research in this area is limited. It is also known that the leptin 
receptor is necessary for the activation of the leptin protein, making it an important 
protein to consider. Furthermore, single nucleotide polymorphisms (SNPs) and DNA 
methylations of the leptin and leptin receptor genes (LEP and LEPR respectively) may 
provide important insight on the relationship that leptin has with inflammation in the 
body.  
Objectives: This dissertation focused on: 1) the association between leptin and leptin 
receptor gene polymorphisms and lung function (forced vital capacity, FVC; forced 
expiratory volume in 1 second, FEV1; and FEV1/FVC) at ages 10 and 18. 2a) The 
association between LEP SNPs and LEP DNA methylation. 2b) The association between 
LEP DNA methylation and serum leptin levels. 3) The association between leptin and 
FVC, FEV1, and FEV1/FVC controlling for body mass index (BMI).  
Methods: The Isle of Wight (IOW) birth cohort, a population-based sample of 1,456 
infants born between January 1989 and February 1990, was prospectively assessed at 
ages 1, 2, 4, 10, and 18 years. FVC, FEV1, and leptin were collected at 10 and 18-year 
follow-ups. SNP and DNA methylation data was analyzed from blood that was collected 
at birth and 18 years follow up respectively. Regarding associations between LEP and
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 LEPR SNPs and FVC, FEV1, and FEV1, FVC, forty-two independent repeated 
measurement analyses were conducted to test their association. Linear regression 
analyses were used to test the links between LEP SNPs and LEP DNA methylation, as 
well as the association between LEP DNA methylation and serum leptin protein levels at 
age 18. Finally, linear regression analyses were applied to investigate the association 
between serum leptin levels at ages 10 and 18 and FVC, FEV1, and FEV1/FVC at ages 10 
and 18.   
Results: LEPR SNPs rs6669354, rs1137101, and rs3762274 were associated with 
decreased lung function from ages 10 to 18. Those with the AC genotype of rs6669354 
had 0.092 L lower FVC and 0.10 L lower FEV1 than those with the AA genotype 
(Adjusted P-value=0.015 for both tests). A similar pattern was observed for SNPs 
rs1137101 and rs3762274 and the association with decreased FEV1/FVC (Adjusted P-
values 0.04 and 0.02 respectively). LEP SNPs rs11763517 and rs4731429 were both 
found to be related with DNA methylation sites cg00666422 (5’UTR region) and 
cg24862443 (3’UTR region) and LEP SNP rs4731429 was associated with cg00840332 
(TSS200 region). The results were replicated in the second-generation (F2) cohort. 
Regarding leptin in F1, increased methylation of cg00840332 interacting with 
rs11763517 and rs4731429 was associated with decreased leptin serum levels. Lastly, in 
boys, an increase in leptin levels from ages 10 to 18 was related to a 0.017 L decreased 
FVC at age 18 (STD=0.007, P-value=0.018), while in girls increased leptin between ages 
10 to 18 was associated with FEV1 at age 18 decreasing by 0.013 L (STD=0.006, P-
value=0.029).  These associations were seen even after controlling for BMI.  
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Conclusions: LEPR SNPs are associated with decreased FVC, FEV1, and FEV1/FVC 
from ages 10 to 18. A possible mechanism for this association can be explained through 
the activity of leptin. First, LEP SNPs are associated with increased LEP DNA 
methylation at the start of the gene and decreased LEP DNA methylation at the 3’UTR 
region of the gene; DNA methylation is linked to circulating serum leptin protein levels.  
Second, an increase in leptin protein between the ages of 10 and 18 is associated with 
decreased FVC in boys and decreased FEV1 in girls at age 18. 
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INTRODUCTION AND LITERATURE REVIEW 
 
1.1 BACKGROUND 
Since the cloning of the LEP 1 and LEPR 2 genes and the identification of leptin as 
a pleiotropic hormone 3-20, leptin has been the extensive focus of studies regarding 
hormone regulation of hunger 21, energy expenditure 4,22, and immune system 
homeostasis 5,23-27. Given that weight gain and reduced physical activity in mice was the 
most visible response to leptin deficiency and that leptin was found to be expressed and 
secreted mainly in white adipose tissue 1,3, it was initially believed that leptin’s primary 
role was metabolic. However, it has since been recognized that the adipose tissue is not 
inert but rather is an endocrine organ that releases pro-inflammatory and anti-
inflammatory factors, among them cytokines such as leptin 28.  Leptin is now known to 
play an important role is the body’s host inflammatory response 5, and by extension, in 
the respiratory system 29-35. Leptin is also produced in lower concentrations by other 
tissues, namely peripheral lung tissue (bronchial epithelial cells, alveolar type II 
pneumocytes, and lung macrophages) 36. There is also evidence that suggests that leptin 
plays a key role in lung maturation and development 36,37, that it might be a stimulant of 
ventilation 29-35,38, and that it is involved in respiratory diseases (i.e., obstructive sleep 
apnea hypopnea syndrome, chronic obstructive pulmonary disease, lung cancer, and 
asthma) 37,39-51. It is becoming increasingly clear that the role of leptin in the body’s 
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immune response is widespread, complex, and needs to be better understood, especially 
in humans.  
 To start understanding the mechanism behind leptin’s role in the body’s host 
inflammatory response and, more specifically, in respiratory illnesses, this dissertation 
focused on the association between leptin and leptin receptor gene polymorphisms and 
lung function (FVC-forced vital capacity; FEV1-forced expiratory volume in 1 second, 
and their ratio FEV1/FVC) while also considering the role of the circulating serum leptin 
protein as an intermediary in the above association. These measurements were considered 
at two different time points, ages 10 and 18 years of age. FVC, FEV1, and FEV1/FVC 
assessments are measured markers that clinicians rely upon to identify asthmatic patients 
and are therefore useful in human models. The LEP gene codes for the leptin protein and 
is vital in understanding this relationship. However, knowledge of a potential association 
between LEP and lung function is currently ambiguous as there are few studies that have 
been conducted in humans and those available yield conflicting results. For example, a 
single nucleotide polymorphism (SNP) of LEP (rs2167270) has been found to be 
associated with FVC and FEV1 
52 in one study while another study has found no 
association between the same SNP and lower respiratory quotient 53.  
Given that leptin activates subsequent processes by binding to the leptin receptor 
(LEPR), the LEPR gene also needs to be considered. The leptin receptor is a member of 
the class I cytokine receptor super-family and is present in many tissues, including the 
lung epithelium 52. A complementary step is to investigate a possible link between LEPR 
SNPs and lung function. As with LEP genes, LEPR and LEPROT (leptin receptor 
overlapping transcript) genes have not been extensively explored in human populations 
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and leave room for further inquiry. Hansel et al found 21 LEPR SNPS to be associated 
with FEV1 decline in patients with chronic obstructive pulmonary disease 
54 while van 
den Borst et al found no association between two LEPR SNPs (that were included in the 
21 SNPs from Hansel et al) and FEV1 or FVC 
52.   
 Not only does the association between LEP and LEPR SNPs with lung function 
need to be further explored but there needs to also be a better understanding of how the 
protein product of these genes influences/mediates this relationship. This involves first 
considering a potential association between SNPs and circulating leptin levels and 
second, examining a relationship between protein leptin levels and lung function. It is 
important to note that plasma leptin levels have been observed to be higher in girls than 
boys during and after puberty 55-58. Blum et al found that plasma leptin levels increased in 
girls, and decreased in boys after pubertal assessment of Tanner stage 2 and found a 
significant gender difference, especially in late puberty and adolescence, even after 
adjustment for body mass index (BMI) or body fat percent 55. This is in accordance with 
the observation that testosterone inhibits the expression of leptin in the body while 
ovarian sex steroids have the opposite effect 55,59,60. Therefore, boys and girls should be 
considered separately when evaluating leptin protein levels. It is also important to look at 
leptin levels throughout puberty (ages 10 and 18 years in our data) because this is the 
period when sex hormone levels fluctuate substantially in boys and girl, thereby 
influencing leptin levels.  
When investigating the effect of genetic activities on protein leptin levels 
additional consideration of DNA methylation can provide a more complete picture. DNA 
methylation represents a change in the activity of the gene that does not involve a 
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mutation (genetic variation or single nucleotide polymorphism, SNP). This change can be 
inherited as a result of past environmental exposures. In a recent article, Yousefi et al 
found that that LEPR SNPs in interaction with in utero smoking exposure were 
associated with LEPR DNA methylation levels and that LEPR DNA methylation was in 
turn associated with serum leptin levels. This two-step analysis revealed that a study of 
DNA methylation and genetic variants is more powerful than the single analysis of 
genetic variants 61. As part of understanding the mediating effect of circulating body 
leptin levels, this dissertation repeated the above-mentioned analysis with LEP SNPs and 
LEP DNA methylation and additionally, taking circulating body leptin levels into 
account. This investigation provides the needed synthesis of the interplay of SNP, DNA 
methylation, and environmental exposures on protein levels that is currently missing in 
the literature (briefly mentioned below and explained in more depth in the literature 
review). 
Depending on the SNP and SNP location, LEP genes have been associated with 
increased or decreased protein leptin levels. Fourati et al found that the following LEP 
SNPs were associated with elevated plasma leptin levels (hyperleptinemia):  rs1349419, 
rs12535708, rs10487506, rs11770725, rs12535747, rs7799039, and rs2167270 62. Two 
other human studies have found an inverse relationship between LEP SNPs and plasma 
and breast tissue leptin levels 63,64. Regarding LEPR SNPs in humans, the LEPR SNP 
(rs1137101) and rs17412175 have been shown to be associated with increased leptin 
levels in Pacific Islander 65 and English populations 61 respectively, while two other 
studies observed no association between genetic variations of the LEPR gene and serum 
leptin levels 66,67.  
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In a study by Hillemacher et al that looked at 130 men and 34 women 7 days after 
alcohol cessation, LEP DNA methylation in the promoter region of the gene was 
associated with increasing serum leptin levels in alcohol dependent patients who were 
going through withdrawal 68. There is a body of evidence that points to prenatal factors 
influencing adult risk of developing various chronic diseases 69. Therefore, it was 
important for us to investigate environmental factors that can influence prenatal 
conditions. With regard to leptin, there is specific evidence that leptin plays an important 
role in prenatal development; LEP methylation has been found to be negatively correlated 
with placental gene expression in male infants 70. Given the placenta’s role in controlling 
in utero growth and development 71 and there is evidence placental genetic and DNA 
methylation profiles may serve as markers of the intrauterine and extra-uterine 
environment 72. In addition, studies have found a positive, significant correlation between 
leptin levels in cord blood and birth weight 73-75; large for gestational age babies had 
higher leptin levels in cord blood compared to appropriate for gestational age babies 75. 
To further knowledge on prenatal influences, we considered the in utero environmental 
exposure, maternal smoking. Beyond that, genetic variants also have been found to affect 
the susceptibility of genes to methylation, a process named allele-specific genotype-
dependent DNA methylation, or methylation quantitative trait loci methQTL 76-82.  
Inconsistent reports on how protein leptin levels are associated with lung function may 
now be explained by accumulating evidence that leptin is both a pro-inflammatory and 
anti-inflammatory cytokine 83. Leptin contributes to protection from infectious agents but 
also to a loss of tolerance and autoimmunity. Reduction in the level of circulating leptin 
(from malnutrition or genetic leptin deficiency) results in impaired Th1 response and 
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induction of Treg cells, thus reducing the immuno-competence in mice 84 and humans 85 
increasing susceptibility to infection. (Th1 helper cells are involved in response against 
intracellular parasites). Conversely, a high amount of leptin secreted by adipocytes (from 
obesity or genetic leptin receptor deficiency) leads to a high frequency and expansion of 
Th1 cells and increased secretion of pro-inflammatory cytokines, on one side, and a low 
proportion of proliferation of Treg cells infiltrating adipose tissue, on the other 83. Leptin 
is involved with body’s innate and adaptive response and has effects on many cells that 
are ultimately related to IL1, IL6, IL-10, IL-1Ra, nitric oxide, LB4, CTA1, COX-2, CD1 
1b, IL-1β, IL-8, TNF-α, INF-γ, IL-12, IL-18 and IgG1 86,87.  
Contradictory findings on the association between serum leptin levels and lung 
function could therefore be due to the fact that leptin signals different immune pathways 
depending on its concentration in the body. An example of these contradictory findings 
are van den Borst et al not finding an association between serum leptin levels and FEV1 
52 
while a large middle-age US sample found a relationship between impaired FEV1 and 
increased serum leptin levels 88. Hickson et al detected an inverse association between 
serum leptin levels and predicted FEV1 and predicted FVC % independent of adiposity 
(total body weight, waist circumference, and BMI) in an African American population 
women of a normal body weight (the models were also adjusted for age, education, 
smoking status, pack-years of cigarette smoking, respiratory medication use, and 
menopausal status in women) 89. Childhood lung infection and asthma have also been 
related to increased plasma leptin levels, and may be related to maximally attained lung 
function 48.  
This dissertation investigated 1) an association between LEP and LEPR SNPs with 
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FVC, FEV1, and FEV1/FVC in a longitudinal analysis looking at ages 10 and 18 years, 2) 
the relationship between LEP and LEPR SNPs and protein leptin levels at age 18, 
considering intermediary role of LEP DNA methylation, and 3) the association between 
leptin and FVC, FEV1, and FEV1/FVC independent of BMI in concurrent and time delay 
models at ages 10 and 18.  
 
1.2 OVERALL DOCUMENT STRUCTURE 
This dissertation is divided into the following sections: 
i. A literature review (Chapter 1, continuation of current chapter) that summarizes 
previous findings investigating the role of leptin in lung function.  
ii. A methods section (Chapter 2) that addresses in detail the study methodology for this 
work including the statistical procedures that were applied for the data analysis. 
iii. A results section (Chapters 3, 4, 5) of three manuscripts, with each chapter comprising 
of a journal article that will be submitted to peer‐ reviewed journals for publication. 
Manuscript 1. LEPR SNPs are associated with lung function: a longitudinal 
analysis 
Manuscript 2. LEP SNPs and DNA methylation influence serum leptin levels in 
boys and girls: Two-stage model of epigenetic analysis 
Manuscript 3. Leptin associated with lung function independent of body mass 
index 
iv. Finally, a concluding discussion chapter (Chapter 6) that synthesizes the findings from 
the three journal articles. 




1.3 LITERATURE REVIEW 
 
1.3.1 BRIEF OVERVIEW OF LEPTIN AND LEPTIN RECEPTOR PROTEINS 
 
Leptin is a 15 kDa protein that consists of 167 amino acids 1. The protein is coded 
by the LEP (or ob) gene which is located on chromosome 7 in humans 1. The LEP gene 
was first cloned in 1994 at the Jackson Laboratory following the observation of the 
random occurrence of mutant mice that weighed three times as much as the wild type 
mice 1. These mice had a mutation of what was then named the ob gene that prevented 
the functional expression of a protein that is now called leptin. Because of this, leptin was 
initially suspected to only play a role in appetite regulation and obesity/adiposity.  
While leptin is known to be mainly synthesized and secreted by white adipose 
tissue 3, it has also been found in human placenta 90, gastric fundic mucosa in rats 91, 
human pancreas 92, fetal baboon lung tissue 93, fetal rat lung fibroblasts94, and in human 
peripheral lung tissue (bronchial epithelial cells, alveolar type II pneumocytes, and lung 
macrophages) 36,37. The regulation of leptin secretion in the body also appeared to be 
straightforward at first. In mouse models, it was observed that food intake lead to 
decreased leptin levels while food consumption resulted in transient increases in leptin 
expression 21 suggesting leptin’s role as an appetite regulator. This supported the initial 
observations mentioned above of leptin deficient mice having greater weight and lower 
resting metabolic rate. However, in humans it was observed that obesity was associated 
with increased leptin levels, suggesting leptin resistance in the body beyond a certain 
weight 95,96 and therefore challenging the previo usly understood linear relationship 
between weight and leptin observed in mouse populations.  Since its discovery, leptin has 
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also been found to play a role in the body’s immune response 5,8-10,12-17,97, stimulation of 
insulin secretion and fatty acid oxidation 19, and reduction of cortisol synthesis 20.  
The leptin receptor is a member of the class I cytokine receptor super-family and 
is coded by the LEPR (or Ob-R) gene 2. Of particular interest for this dissertation is the 
expression of the LEPR gene in lung tissue in mice, rats, baboons, and other animals 
93,94,98-104, contributing to the interest of the role of LEPR in human lung function. 
Previous findings therefore support the idea that leptin and leptin receptor are 
involved with processes in the lung and could be linked to lung diseases such as asthma.  
Hence, a logical step is to explore the association of LEP and LEPR genes with lung 
function. 
 
1.3.2 LEP AND LEPR SNPS AND LUNG FUNCTION 
LEP SNPs (rs2167270, rs13228377, rs2167270) have generally been associated 
with lowered respiratory performance. One study in humans found an association 
between the A allele of LEP 19 G>A LEP SNP and decreased FEV1 and FVC 
52 while 
another study found an association between 3’UTR A/G and -2549 A/G LEP SNPs and 
asthma 105. Ob/ob (leptin deficient mice) mutant mice were observed to have lower lung 
volume and alveolar surface area compared the wild type mice 106. Ob/ob mice also 
developed rapid breathing patterns, altered baseline breathing patterns, and depressed 
hypercapnic ventilatory response. The latter was present before the mice became obese, 
demonstrating deteriorated respiratory control independent of body mass index (BMI). 
Total lung capacity and lung compliance were halved in ob/ob mutant mice 32.  
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In humans, LEPR gene expression has been observed in human airway smooth 
muscle cells 107, epithelial cells, and submucosa of lung tissue obtained by bronchial 
biopsies 108. In two human studies, there was no association found between the rs1137100 
and rs1137101 LEPR SNPs and lung function and asthma respectively 52,105. Hansel et al 
found that 21 LEPR SNPs (rs7531867, rs1805096, rs1892535, rs6588153, rs1938484, 
rs12564626, rs10443259, rs6691346, rs4655680, rs1137100, rs6702028, rs1782763, 
rs1171265, rs1171271, rs1782754, rs1171274, rs10889558, rs1327121, rs17412682, 
rs2025804, rs9436746) were associated with lung function decline in a subset of the Lung 
Health Study European Cohort 54. 
 
1.3.3 LEP DNA METHYLATION  
Current information on LEP DNA methylation is sparse. The literature shows a 
trend for increased DNA methylation in the promoter region correlating with poor health 
outcomes. Lesseur et al has found that LEP epigenetic control may be influenced by 
perinatal factors. For example, cord blood LEP methylation was found to be higher in 
small for gestational age babies and genotypes of rs2167270 LEP SNPs 109. In a 
following study by Lesseur et al 70 LEP methylation for placental samples of healthy term 
babies showed negative correlation with LEP gene expression, only in male participants. 
Higher LEP DNA methylation was also associated with increased lethargy and 
hypotonicity, again, only in males in the study. In a small case-control study, mean DNA 
methylation of proximal LEP promoter was increased in low birth weight men 110.  
Although DNA methylation can be stable throughout one’s life, it can be 
modified by environmental factors. Data from the Dutch Famine Birth Cohort have 
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reported higher blood LEP methylation levels in adult men who were prenatally exposed 
to war-time famine in 1944-45 compared to unexposed siblings 111. This suggests that an 
outside variable may have influenced the LEP DNA methylation. It is therefore valuable 
to consider an environmental component in the analysis of the association between 
genetic variants, DNA methylation, and leptin concentrations. The specific choice of an 
environmental variable for this dissertation is one that is prenatal and influences prenatal 
development. During pregnancy the placenta is where maternal exposures, such as 
smoking, are translated and can affect fetal programming. Therefore, a variable that 
represents the time period of this exposure can provide insight onto how changed in LEP 
methylation can affect leptin levels in the body later in life. 
 
1.3.4 PROTEIN LEPTIN LEVELS, IMMUNE RESPONSE, AND LUNG FUNCTION 
Leptin’s role in the body’s immune response involves connections between food 
intake, metabolism, and immune homeostasis 3,83. The hypothalamic-pituitary-adrenal 
(HPA) axis is one of the main structures that is responsible for this connection and this 
axis secretes hormones during inflammation to control the body’s immune response. 
Leptin and leptin receptor are expressed in the hypothalamus and the pituitary gland 
while only the leptin receptor is expressed in the adrenal gland 112. Leptin, in conjunction 
with leptin receptor, regulates the secretion of HPA hormones.  Studies in mice have 
shown that leptin has both a direct and indirect effect on the body’s immunity via the 
modulation of central or peripheral pathways 113. Leptin’s role in the body’s immune 
response varies depending on how much serum leptin is circulating in the blood. If there 
are low amounts of leptin in the body (hypoleptinaemia) then Th1 cells are impaired and 
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Treg cells proliferate, leading to increased infections and disease susceptibility 
(tuberculosis, candida, pneumonia). If the body has an excess of leptin 
(hyperleptinaemia), then Treg cells are inhibited and Th1 cells increase the secretion of 
proinflammatory cytokines, leading to increased autoimmune disease susceptibility 
(multiple sclerosis, rheumatoid arthritis). When the body has the appropriate moderate 
levels of leptin, there is Th1/Th2/Treg balance and the body has an optimal immune 
response.   
Leptin affects both the body’s innate and adaptive immunity. Studies on human 
and animal models have found the following associations between leptin and immune 
process in the body. Regarding innate immunity, leptin binds to it receptors in 
monocytes, macrophages, neutrophils, eosinophils, dendritic cells, and natural killer cells. 
In monocytes and macrophages, leptin is associated with increased phagocytosis and 
increased secretion of IL-1, IL-6, and TNFα. It is also linked to increased expression of 
activation markers, increased expression of surface markers, and increased eicosanoids, 
nitric oxide, leukotriene B4, cholesterol acyltransferase 1, and cyclooxygenase-2. In 
neutrophils, leptin seems to increase the formation and release of reactive oxygen species, 
increases chemotaxis, decreases apoptosis, and increases the expression of CD1 1b. In 
eosinophils, leptin is associated with increased expression of adhesion molecules, 
increased chemokinesis, and increased release of IL-1β, IL-6, and IL-8. In dendritic cells, 
leptin is associated with increased IL-1β, IL-6, IL-8, IL-12, and TNF-α. Lastly, in natural 
killer cells leptin plays a role in increased proliferation and maturation, increase 
differentiation activation, and cytoxicity 86. 
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When looking at adaptive immune response, human and animal studies have 
found that leptin affects thymoctyes, naïve T cells, memory T cells, activates Th1 cells, 
inhibits Th2 cells, Treg cells, B cells, and Natural Killer T cells. In thymocytes leptin is 
associated with increased maturation and decreases apoptosis 86. In Naïve T cells, leptin 
increase proliferation and decreases apoptosis. In memory T cells, leptin binds to its 
receptor and decreases proliferation. In Th1 cells activation, leptin increases the IgG2a 
switch, increases TNF-α, and increases TNF-γ. During Th2 cell inhibition, leptin 
decreases IgG1 switch, and increases secretion of IL-10 5,22. In Treg cells, leptin increases 
anergy (absence of immune response), and increases hyperresponsiveness. In B cells, 
leptin decreases apoptosis and increases secretion of IL-12, IL-6 and TNF-α. In natural 
killer cells, leptin increases proliferation.   
Of the cytokines that leptin may affect, IL-10 and IL-12 are available in our 
dataset. Furthermore, IL-10 and IL-12 are potentially linked to lung function and asthma, 
In a prospective study, IL-10 polymorphisms were associated with obstructive lung 
function parameters, suggesting as important role if IL-10 in the development of lung 
function deficiency in early bronchitis patients 114. Similarly, a longitudinal study of 379 
firefighters with at least six annual FEV1 measurements found that those with IL-10 
SNPs had different rates of decline in lung function as they aged 115  
 
Studies in animals have suggested that leptin is involved in respiratory control. 
For example, when comparing mutant LEP mice to their wild type counterparts and even 
before the onset of obesity, the mutant mice have increased breathing frequency, minute 
ventilation and tidal volume, elevated PaCO2 and depressed hypercapnic ventilatory 
response 38. Chronic leptin administration restores breathing rates and improves lung 
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compliance. However, because leptin administration in mice also decreases weight, the 
improvement of breathing and lung compliance cannot be conclusively attributed to 
leptin therapy and not simply a result of lowered body mass index (BMI). Acute leptin 
replacement, on the other hand, has led to increased baseline ventilation independent of 
weight gain 116, and leptin injections in rat brain has led to increased pulmonary 
ventilation and respiratory volume 29,38. Leptin has also been observed to be involved in 
the regulation of embryonic lung growth and maturation 106,117. Specifically, 
administration of leptin to antenatal mice has led to improved lung development in the 
newborn 117, whereas leptin-deficient mice have been observed to have impaired alveolar 
formation and lower lung volumes at birth 106. Additionally, postnatal leptin treatment of 
these same mice has resulted in increased alveolar surface area and lung volume 106. 
Whereas the consensus in animal models is that higher leptin levels are correlated 
with improved respiratory response, human studies yield either null findings or an inverse 
association. Clinical studies have found that leptin is a predictor of lung function in 
asthma patients 35 and is negatively correlated to lung volumes in COPD patients 118 and 
clinical severity of asthma 119. Van den Borst et al observed no association between FEV1 
and serum leptin levels but found that increased serum leptin levels were associated with 
decreased FVC in men but not in women 52. There has also been an observed inverse 
association between serum leptin levels and lung function in an African American 
population 89 and a twin population 52. Sin et al in a large sample (N=2808) also observed 
an inverse association between serum leptin levels and FEV1 and FVC% predicted, 
independent of adipocytes in men but found no such pattern in women 88. In a study 
involving pre-pubertal boys and girls, increased leptin levels were associated with asthma 
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only in boys 48. In an Indian population, increased plasma leptin was associated with 
decreased FEV1 but no association was found with FVC.  
While sleep apnea cannot be tested from the data available in this study, it is 
important to note that the increasing scope of leptin’s influence in the respiratory system 
includes the hypothesis that obstructive sleep apnea syndrome (characterized by repeated 
episodes of partial or complete upper airway obstruction) is a leptin-resistant state. 
Impaired leptin activity in the central nervous system due to a down-regulation of leptin 
receptors (54, 76-78) can be responsible for the above hypothesis and is supported by 
findings of a LEPR SNP being associated with obstructive sleep apnea syndrome (79) but 
not confirmed by another group (80). Patients with untreated asthma have shown 
decreased leptin expression in their bronchial epithelium (ex vivo) 108.  
Although there is strong evidence that leptin plays a role in the respiratory system, 
it is difficult to isolate this role from other factors, such as BMI. Hence there is a need to 
control BMI when assessing the risk related to lung function when assessing leptin.  
Furthermore, while animal studies show a consistent reaction to leptin levels in the body, 
human studies show an opposite effect that may be stratified by sex and endocrine 
changes during puberty 
 
1.3.5 GAPS AND LIMITATIONS IN THE CURRENT LITERATURES 
- Investigations into the associations between LEP SNPs and lung function only 
considered one SNP in the intron region of the gene 52,53. Investigations into the 
associations between LEPR SNPs and lung function by Loos et al only looked at SNPs 
that consisted of benign missense mutations (mutations that results in genes that code for 
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a different amino acid but still express the same protein) and mutations that occurred in 
the intron region of the gene53. Only one study has included SNPs that were in the 
promoter or 3’ UTR region of the gene or investigated lung function measurements at 
multiple time points 54. Lastly, no study has investigated this relationship stratified by sex 
or at multiple time points throughout puberty.  
- The DNA methylation data used in this dissertation was collected with the 
Infinium Human Methylation 450 array, which is reported to have superior 
reproducibility and validity than other methods 120,121. Of the studies that investigated an 
association between DNA methylation and leptin levels, none used this method of DNA 
methylation assessment. 
- No studies have analyzed the association between methQTLs and DNA 
methylation or employed the two-step analysis for understanding the mechanism behind 
an association between LEP SNPs interacting with in utero smoking exposure and serum 
leptin levels. 
- No studies have explored and association between serum leptin levels and lung 
function independent of BMI while stratifying by sex. Given that leptin is inhibited by 
testosterone but increased by ovarian sex steroids 5, any analysis involving leptin and 
BMI should consider boys and girls separately. 
- Studies investigating the association between leptin levels and lung function, do 
not take into account the change in leptin levels during puberty 119. 
 
1.4 SPECIFIC AIMS AND HYPOTHESES 
This dissertation seeks to enhance our understanding of the association between 
LEP and LEPR SNPs and lung function as how this relationship is mediated by leptin. 
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Furthermore, this dissertation aimed to demonstrate the LEP SNP leptinlung 
function mechanism while taking into consideration the role of epigenetics. In all 
analyses, boys and girls were either considered separately or sex was controlled as a 
confounder in the models.   
 
Specific Aim 1: The association between LEP and LEPR SNPs and lung function at ages 
10 and 18 years.  
Hypothesis 1: LEP and LEPR SNPs are associated with lung function measures of FVC, 
FEV1, and FEV1/FVC at ages 10 and 18 and this association is gender-specific. 
 
Specific Aim 2: Investigate LEP SNPs that are potential methQTLs interacting with in 
utero smoking exposure. DNA methylation sites that are identified in the methQTL 
analysis are associated with serum leptin concentrations. 
Hypothesis 2a: LEP SNP interacting with in utero smoking exposure is associated with 
LEP DNA methylation at age 18 and this association is gender-specific. 
Hypothesis 2b: LEP DNA methylation sites found in 2a are associated with protein leptin 
levels at age 18 and this association is gender-specific. 
We also tested whether hypothesis 2a can be replicated in the subsequent generation of 
the Isle of Wight birth cohort (F2-generation). 
 
Specific Aim 3: IL-10 and IL-12 mediate the association of leptin with lung function at 
ages 10 and 18.  
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Hypothesis 3: Serum leptin levels at ages 10 and 18 are associated with lung function 
measures of FVC, FEV1, and FEV1/FVC at ages 10 and 18, using IL-10 and IL-12 as 
intervening variables in change models. These associations were stratified by sex.  
Theoretical path model: 







2.1 STUDY DESIGN AND PARTICIPANTS 
A whole population birth cohort was established on the Isle of Wight, UK, in 
1989 to prospectively study the natural history of allergies from birth to 18 years of age. 
Ethics approvals were obtained from the Isle of Wight Local Research Ethics Committee 
(now the National Research Ethics Service Committee South Central – Southampton B). 
Of the 1,536 children born between January 1, 1989, and February 28, 1990, written 
informed consent was obtained from parents to enroll 1,456 newborns. Children were 
followed up at the ages of 1 (n=1,167), 2 (n=1,174), 4 (n=1,218), 10 (n=1,373), and 18 
years (n=1,313). The IOW birth cohort has been described in detail elsewhere 122. 
Detailed interviews and examinations were completed for each child at each follow-up. 
When a visit was not possible, a telephone questionnaire was completed or a postal 
questionnaire was sent. Information on maternal smoking during pregnancy was obtained 
from mothers at the time of recruitment (birth). 
 
2.2 LEPTIN CONCENTRATIONS 
Leptin concentrations were obtained from blood samples collected at ages 10 and 
18 years. Aliquots of blood serum that were isolated from the blood samples were used in 
enzyme-linked immunosorbent assays from Biokit, S.A. (Barcelona, Spain). The assays 
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were conducted according to the manufacturer’s kit instructions. Each sample, including 
standards and the blank, was assayed in duplicate. As part of the repeated follow ups, the 
original questionnaire-based information was updated and weight and height of the child 
were measured at age 18 years.  
 
2.3 LEP, LEPR, AND LEPROT GENOTYPING AND DNA METHYLATION ANALYSIS 
LEP SNPS (k=4) and LEPR SNPs (k=21) that tagged the LEP, LEPR and 
neighboring LEPROT genes were identified using Tagger implemented in Haploview. 
Leptin receptor overlapping transcript (LEPROT) was included in the analysis because it 
shares the same promoter and the first two exons as the LEPR gene. DNA was extracted 
from blood or saliva samples from cohort subjects (n=1,211). DNA samples were 
interrogated using Golden Gate Genotyping Assays (Illumina Inc, San Diego, CA) on the 
Bead Xpress Veracode platform (Illumina, Inc, San Diego, CA) per Illumina’s protocol 
120,121. In brief, samples were fragmented and hybridized to the pool of allele-specific 
primer sets. Following an extension/ligation reaction the samples were then hybridized to 
the Veracode bead pool and processed on the Bead Xpress reader. Data were analyzed 
using the genotyping module of the GenomeStudio Software package (Illumina, Inc, San 
Diego, CA). DNA from each subject plus 37 replicate samples were analyzed. The 
quality threshold for allele determination was set at a GenCall score 0.25 (scores #0.25 
were ‘‘no calls’’) with 98.3% retained for further analysis. Analysis of each locus 
included reclustering of genotyping data using our project data to define genotype cluster 
positions with additional manual reclustering to maximize both cluster separation and the 
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50th percentile of the distribution of the GenCall scores across all genotypes (50% GC 
score). 
For measuring methylation levels, DNA was extracted from whole blood 
collected at age 18 years from 245 female offspring123 as well as 125 males, 100 pregnant 
women, and 130 F2 offspring. One microgram of DNA was bisulfite-treated for cytosine 
to thymine conversion using the EZ 96-DNA methylation kit (Zymo Research, CA, 
USA), following the manufacturer’s standard protocol. Genome-wide DNA-M was 
assessed using the Illumina Infinium Human Methylation 450 Bead Chip (Illumina, Inc., 
CA, USA), which interrogates>484,000 CpG sites associated with approximately 24,000 
genes. Arrays were processed using a standard protocol as described elsewhere 120, with 
multiple identical control samples assigned to each bisulphite conversion batch to assess 
assay variability and samples randomly distributed on microarrays to control against 
batch effects. The Bead Chips were scanned using a Bead Station, and the methylation 
level (beta value) calculated for each queried CpG locus using the Methylation Module of 
Bead Studio software. 
Concentrations of IL-10 and IL-12 cytokines were measured using the 
electrochemiluminescence Meso Scale Delivery (MSD) Kit platform from blood samples 
collected at age 18 years (Meso Scale Discovery, Rockville, Maryland, USA), known for 
of higher sensitivity, lower level of detection, and wide dynamic range with the standard 
curve being linear within the range of experimental samples 124. All experiments were 
performed according to the manufacturer’s instructions with minimal modifications and 
optimization. Briefly, 50 μl of each 1:2 diluted sample was added to each well of the pre-
coated 96-well plate and incubated at room temperature (RT) for 2.5 h with continuous 
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counter-clock-wise shaking. The plates were then washed three times with 1× Wash 
Buffer (MSD) and Sulfotag Detection Antibody Cocktail (MSD) was then added to each 
well and the plates then incubated for an additional 2 h with shaking at RT. Finally, the 
plates were washed again, and were scanned by a SECTOR® Imager 6000 Reader 
(MSD) after adding 150 μl of 2× Read Buffer (MSD). 
 
2.4 STATISTICAL ANALYSIS 
2.4.1 SA1: HYPOTHESIS 1 
LEP and LEPR SNPs are associated with lung function measures of FVC, FEV1, 
and FEV1/FVC at ages 10 and 18 and this association is gender-specific.  
To identify haplotype blocks, linkage disequilibrium analysis was performed on 
fourteen LEPR SNPs and seven LEPROT SNPs with Haploview 4.2 125, using the Gabriel 
et al. method 126. We then selected one SNP from each block based on what was 
previously chosen in Yousefi et al 61. All four LEP SNPs were tested for their association 
with FVC and FEV1 at age 18 years.  
Linear mixed models were used to test the association between LEP, LEPR, and 
LEPROT SNPs and lung function at ages 10 and 18. With 10 LEPR/LEPROT SNPs and 4 
LEP SNPs, and three measures of lung function (FVC, FEV1, and FEV1/FVC) this 
resulted in 42 individual tests. Each dependent lung function variable (FVC, FEV1, 
FEV1/FVC) was analyzed in a separate model and data from ages 10 and 18 years were 
analyzed in the same model. The following variables also had data at both years: age at 
follow up, BMI, and height. The full mixed model was controlled for the following 
confounders: age at follow up (years), sex (male, female), in utero smoking exposure 
23 
 
(yes, no), parental asthma status (mother, father, both, or none), ever smoking (yes, no), 
SES group (low, middle, high), birth weight (kg), height (cm), BMI (kg/cm2), and 
duration of breastfeeding (weeks).  An autoregressive covariance structure was used. 
Manual backward elimination of confounder applying the 10% rule was used to 
determine the most appropriate model.  
False discovery rate (FDR) was used to adjust for multiple testing 127. FDR was 
applied separately, once with tests involving LEPR and LEPROT SNPs only and another 
time looking only at the LEP SNPs.  
 
2.4.2 SA2A: HYPOTHESIS 2A 
LEP SNP interacting with in utero smoking exposure is associated with LEP DNA 
methylation at age 18 and this association is gender-specific. We will attempt to replicate 
this analysis in the F2 population. 
Haplotype analysis was performed on LEP SNPs in the F1 and F2 generation of 
this cohort (note: Mukherjee et al has performed the analysis in the F1 cohort in a 
previous publication that we used in this study as well 128). We used one SNP from each 
haplotype block and proceeded with the following analyses.  
F1 population: To identify methQTLs modified by gestational maternal smoking, 
modeling was performed by using LEP SNPs and their interaction with in utero smoking 
exposure to predict the methylation of LEP CpG sites. Each CpG (M-values) was 
modeled against rs11763517, rs4731429, and rs10954176, with each SNP interacting 
with in utero smoking exposure. In addition, all models were controlled for cell-
composition to ensure that we were indeed observing associations with DNA methylation 
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un-confounded by the proportion of these cells. We controlled for levels of the following 
cells: B-cells, granulocytes, monocytes, natural killer cells, eosinophils, and CD4 T-cells. 
These cell counts were obtained from breast cancer patients from the Winship Cancer 
Institute 129, 61 subjects at baseline and 39 subjects at six-month-follow-up. We followed 
the method used by Kaushal et al 130 where 484,489 CpG sites were tested against cell 
types. The most parsimonious model was determined via backward elimination using the 
10% rule, first by removing interaction terms followed by individual SNPs. False 
discovery rate was used to adjust for multiple testing.  
F2 Population: The methQTL analysis was replicated in the F2 population 
(offspring of F1). Eighteen LEP SNPs were genotyped in the F2 population but only 5 
SNPs (rs2167270, rs2278815, rs11760956, rs11763517, rs12706832) proved to have 
polymorphisms (the others were monomorph, with all or almost all the population having 
one of the possible genotypes). Haplotype analysis using Haploview software 125 revealed 
that SNPs rs2278815 and rs12706832 were in LD with each other while SNPs 
rs11763517 and rs11760956 were in LD with each other (Figure 4.1). Therefore, the 
methQTL analysis included the following SNPs interacting with in utero smoking 
exposure predicting DNA methylation levels: rs2278815, rs11763517, and rs2167270. 
While SNPs in the F1 populations were collected via selected probes, those from the F2 
children were from a genome-wide product. Therefore, the following SNPs, rs2167270, 
rs2278815, rs11760956, and rs12706832 were not identical with the SNPs identified in 
the F1 population. Hence, in order to see if the findings in the F2 population are based on 
closely related SNPs, we generated a second LD plot using the International Haplotype 
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Map (HapMap) project data from the Central European University database 131 (Figure 
4.2).  
 
2.4.3 SA2B: HYPOTHESIS 2B 
LEP DNA methylation sites found in 2a are associated with protein leptin levels 
at age 18 and this association is gender-specific. 
The selected CpG sites (M-values) from hypothesis 2a were tested on whether 
they modified the association that LEP SNPs had with leptin serum concentrations at age 
18. In this step, our focus was on the interaction effects and false discovery rate was 
applied to correct for multiple testing among the tests for interaction effects between CpG 
sites and genetic variants. For both sets of statistical analyses, the GLM procedure was 
used in SAS 9.4 (SAS, Gary, NC, USA). In addition, because leptin levels vary greatly 
between boys and girls following puberty, all models initially controlled for sex. As the 
proportion of girls in the subsample with DNA-methylation was higher than the 
proportion of boys, the analyses were weighted for sex. Since the same SNP (rs4731429) 
that was a methQTL for cg00840332 was also a genetic modifier in the association 
between DNA-M and leptin levels, we calculated the residuals from the association 
between rs4731429 and cg00840332 using linear regression analyses. These DNA-







2.4.4 SA3: HYPOTHESIS 3 
Hypothesis 3: Serum leptin levels at ages 10 and 18 are associated with lung 
function measures of FVC, FEV1, and FEV1/FVC at ages 10 and 18, using IL-10 and IL-
12 as intervening variables in change models. These associations are stratified by sex.  
Spearman correlations were used to initially check for associations between the 
cytokines (IL-10 and IL-12) and leptin at ages 10 and 18 and all lung function measures 
at ages 10 and 18. The cytokines were not associated with the exposures or the outcome 
so path analysis could not be performed and IL-10 and Il-12 were not used in subsequent 
analyses. Linear models were used the test the association between leptin and lung 
function (FVC, FEV1, and FEV1/FVC). Two sets of analyses were performed: 1) 
Concurrent models tested the association between leptin at age 10 and lung function at 
age 10 and leptin at age 10 and lung function at age 18 years. 2) Change in leptin levels 
from ages 10 to 18 were employed to predict lung function at age 18 years (time-delayed 
model). Since prior findings suggested variations of the associations by the sex of the 
child, the subgroup of boys and girls were analyzed separately. In the concurrent models, 
we controlled for height and BMI at the respective ages. In the delayed model, we 
controlled for height at age 18, change in height between ages 10 and 18, and change in 




RESULTS I - MANUSCRIPT #1  
LEPR SNPS ARE ASSOCIATED WITH LUNG FUNCTION: 
 A LONGITUDINAL ANALYSIS1 
3.1 INTRODUCTION 
Leptin is an extensively studied pleiotropic cytokine that is commonly known for 
its association with body mass index (BMI) and energy regulation in the body4,21,22. 
However, it is also recognized to play an important role in the body’s host inflammatory 
response, although the mechanism is complex and poorly understood 87,132,133. 
Specifically, with regards to obstructive lung diseases such as asthma, leptin may 
contribute by activating the Janus Kinase 2/Signal Transducer and Activator of Transcript 
3 (JAK2/STAT3) signaling pathway 134-139. It has been proposed that the leptin protein 
binds to the leptin receptor, enabling the JAK2 to bind to the protein-receptor complex. 
This in turn phosphorylates tyrosine residues on the leptin receptor, leading to the 
initiation of the JAK2/STAT3 signaling pathway. This pathway subsequently results in 
the release of pro-inflammatory cytokines, such as Th1, TNF-α, IFN-γ, IL-2, IL-6, and 
IL-12 86, that can lead to airway obstruction diseases. Because of leptin’s involvement 
                                                          
1 M. Yousefi, W. Karmaus, H. Zhang, M Torres, J Burch. LEPR SNPs are associated with lung function: A 
longitudinal analysis. To be submitted. 
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with immune response, changes in leptin and leptin receptor protein structures (resulting 
from genetic variation) may influence respiratory diseases.  
Only a few studies have investigated the relationship between LEP SNPs and 
respiratory outcomes. Animal studies have observed characteristics in mice that have a 
mutation that result in no leptin protein expression (i.e., leptin mutant mice, ob/ob 
knockout mice, leptin deficient mice). These mice have been observed to have lower lung 
volume and alveolar surface area compared to the wild type mice 106, rapid breathing 
patterns, and depressed hypercapnic ventilatory response. The latter has been observed 
before the mice became obese, demonstrating deteriorated respiratory control 
independent of body mass index (BMI). Total lung capacity and lung compliance are also 
halved in ob/ob mutant mice 52. In humans 3’UTR A/G and -2549 A/G LEP SNPs have 
been associated with asthma 105.   
To date, only two studies have investigated the relationship between LEP SNPs 
and lung function specifically. Van den Borst et al found that the AA genotype of 
rs2167270 was associated with declined force expiratory volume in one second (FEV1) 
and forced vital capacity (FVC) compared to the other genotypes52. Mukherjee et al 
found that rs11763517 was associated with decreased FEV1 and FEV1/FVC; however, 
only with increased DNA methylation of the LEP gene 128. This study was the first to 
explore the longitudinal association between LEP SNPs (rs10249476, rs11763517, 
rs4731429, and rs10954176) and FVC, FEV1, FEV1/FVC.   
The leptin protein must bind to the leptin receptor to initiate the pathway that is 
involved in the body’s host inflammatory response. Therefore, it is important to also 
consider the LEPR gene when understanding the role of leptin in the body. Evidence that 
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LEPR gene expression has been observed in human airway smooth muscle cells 107, 
epithelial cells, and submucosa of lung tissue obtained by bronchial biopsies 108, suggests 
that it may play a role in respiratory illnesses. However, in a human study no association 
was detected between LEPR SNP rs1137101 and asthma 105. In two human studies, no 
association was detected between the rs1137100 and rs1137101 LEPR SNPs and lung 
function and asthma respectively 52,105 (Table 3.1). Hansel et al (N=429) found that 21 
LEPR SNPs (rs7531867, rs1805096, rs1892535, rs6588153, rs1938484, rs12564626, 
rs10443259, rs6691346, rs4655680, rs1137100, rs6702028, rs1782763, rs1171265, 
rs1171271, rs1782754, rs1171274, rs10889558, rs1327121, rs17412682, rs2025804, 
rs9436746) were associated with lung function decline in a subset of the Lung Health 
Study European Cohort 54. However, when looking at two of the same SNPs investigated 
by Hansel it al (rs1137100 and rs1137101) , van den Borst et al found no association with 
and FEV1 or FVC 
52. It is important to note that both studies had a similar sample size 
and a longitudinal analysis. 
Another gene assisting our understanding in leptin and inflammation is the leptin 
receptor overlapping transcript gene, LEPROT. This gene overlaps with the LEPR (as the 
name suggests), and aids in cell surface expression of the leptin receptor protein. 
 When investigating the relationship between LEP, LEPR, and LEPROT SNPs and 
lung function, it is important to control for potential confounders. It is well documented 
that birthweight is associated with adult lung function. Linear mixed models and path 
analysis in a study by Balte et al revealed that increased birthweight was associated with 
increased FEV1 and FVC at 18 years of age after adjusting for potential confounders 
140. 
Other studies have also found a positive linear relationship between birthweight and lung 
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function in both adults and children 141-143. Maternal smoking during pregnancy has been 
directly associated with FEF25-75 in the Isle of Wight cohort and should therefore be tested 
as a potential confounder 140. Height and age are used to predict lung function against 
spirometry tests and should therefore be included as well. Likewise body mass index 
(BMI) is known to be associated with leptin protein  144,145,  LEP and LEPR genes 
105,146,147, and lung function148. It is known that leptin levels are different between men 
and women 55,149,150, so all analyses need to take sex into account.  In a previous path 
analysis using samples from Isle of Wight cohort that was also analyzed in this work, 
duration of breastfeeding was directly  positively associated with FVC at age 10 and 
indirectly with FVC at age 18 151.  
The genetic data from the Isle of Wight Birth Cohort Study 152 provides a unique 
opportunity to investigate the relationship between leptin (LEP) and (LEPR) single 
nucleotide polymorphisms (SNPs) and lung function. We tested the association of LEP, 
LEPROT, and LEPR SNPs with lung function measured by FVC, FEV1, and FEV1/FVC. 
FVC quantifies lung volume, FEV1 reveals airway obstruction, and the ratio of 
FEV1/FVC shows if there is respiratory distress. In the case of asthma and other 
obstructive lung diseases, there is lower than normal FEV1/FVC. This was only the 
second study to investigate the relationship between these LEP SNPs and lung function, 








3.2.1 POPULATION CHARACTERISTICS 
A whole population birth cohort was established on the Isle of Wight, UK, in 
1989 to prospectively study the natural history of allergies from birth to 18 years of age. 
Ethics approvals were obtained from the Isle of Wight Local Research Ethics Committee 
(now the National Research Ethics Service Committee South Central – Southampton B). 
Of the 1,536 children born between January 1,1989, and February 28, 1990, written 
informed consent was obtained from parents to enroll 1,456 newborns. Children were 
followed up at the ages of 1 (n=1,167), 2 (n=1,174), 4 (n=1,218), 10 (n=1,373), and 18 
years (n=1,313). The IOW birth cohort has been described in detail elsewhere 153. 
Detailed interviews and examinations were completed for each child at each follow-up. 
When a visit was not possible, a telephone questionnaire was completed or a postal 
questionnaire was sent. Information on maternal smoking during pregnancy was obtained 
from mothers at the time recruitment (birth).  
 
3.2.2 LUNG FUNCTION MEASUREMENTS  
FVC and FEV1 were measured at ages 10 and 18 years.  Lung function testing 
was performed using the Koko spirometry software package on a portable desktop device 
(PDS Instrumentation, Louisville, KY, USA) 154.  Tests were performed in accordance 
with American Thoracic Society and European Respiratory Society spirometry guidelines 
6. Children were required to be free from respiratory infection for 14 days and not taking 
systemic oral steroids.  In addition, subjects were asked to abstain from any beta-agonist 
medication for at least 6 hours and from caffeine intake for at least 4 hours prior to 
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testing. Measurements were made in a standardized manner with the subject standing 
without a nose clip 155. Forced vital capacity (FVC) was recorded in liters as the best of 
three consecutive forced expiratory maneuvers. Participants that exhibited clinical 
symptoms consistent with either current infection or a recent (within two weeks) asthma 
exacerbation, which required antibiotics or oral steroid within the preceding two weeks, 
were rescheduled for spirometry testing.  
 
3.2.3 CONFOUNDERS 
 We considered the following as potential confounders: age at follow-up, sex, in 
utero exposure to maternal smoking, history of parental asthma, birth weight, height at 
ages 10 and 18 years, duration of breastfeeding in weeks, if the child ever smoked, and 
socioeconomic status (SES).  
Age at follow-up was calculated by subtracting date of follow-up from date of 
birth. Information on birthweight was obtained from hospital records. Information on 
whether the mother smoked while pregnant, parental history of asthma, and the sex of the 
child was collected after delivery. Breastfeeding duration was ascertained at ages 1 and 2 
years. Socio-economic status was based on three variables: 1) the British socioeconomic 
classes (1–6) derived from parental occupation reported at birth; 2) the number of 
children in the index child's bedroom (collected at age four years); and 3) family income 
at age 10 years. Height and weight were measured before the spirometric tests at age 10 
and 18 years. Height was ascertained via the standard height measurement (cm) used at 
the allergy clinic for those that visited the center. BMI was calculated. Ever smoking 
status was determined by whether the child reported that they currently smoked at age 10 
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or 18 follow up or if the child reported to have ever started smoking (even if they no 
longer smoked at the follow up times). 
The full mixed model was controlled for the following variables: age at follow up 
(years), sex (male, female), in utero smoking exposure (yes, no), parental asthma status 
(mother, father, both, or none), ever smoking (yes, no), SES group (low, middle, high), 
birth weight (kg), height (cm), BMI (kg/cm2), and duration of breastfeeding (weeks).   
 
3.2.4 SNP COLLECTION AND SELECTION 
DNA was extracted from blood or saliva samples from cohort subjects (n=1,211). 
DNA samples were interrogated using Golden Gate Genotyping Assays (Illumina Inc, 
San Diego, CA) on the Bead Xpress Veracode platform (Illumina, Inc, San Diego, CA) 
per Illumina’s protocol [45, 46]. In brief, samples were fragmented and hybridized to the 
pool of allele-specific primer sets. Following an extension/ligation reaction the samples 
were then hybridized to the Veracode bead pool and processed on the Bead Xpress 
reader. Data were analyzed using the genotyping module of the GenomeStudio Software 
package (Illumina, Inc, San Diego, CA). DNA from each subject plus 37 replicate 
samples were analyzed. The quality threshold for allele determination was set at a 
GenCall score 0.25 (scores #0.25 were ‘‘no calls’’) with 98.3% retained for further 
analysis. Analysis of each locus included reclustering of genotyping data using our 
project data to define genotype cluster positions with additional manual reclustering to 
maximize both cluster separation and the 50th percentile of the distribution of the 
GenCall scores across all genotypes (50% GC score). Reference groups or genotypes 
were based on the one that presented the highest frequency.  
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All four LEP SNPs were selected to be used in the analysis. To identify haplotype 
blocks, linkage disequilibrium analysis was performed on fourteen LEPR SNPs and 
seven LEPROT SNPs with Haploview 4.2 125,using the Gabriel et al method 126. This 
resulted in the same haplotype blocks found in Yousefi et al 61, so we selected the same 
SNPs from each block. 
 
3.2.5 STATISTICAL ANALYSIS 
Linear mixed models were used to test the association between LEP, LEPR, and 
LEPROT SNPs and lung function at ages 10 and 18. With 10 LEPR/LEPROT SNPs and 4 
LEP SNPs, and three measures of lung function (FVC, FEV1, and FEV1/FVC) this 
resulted in 42 individual tests. Each dependent lung function variable (FVC, FEV1, 
FEV1/FVC) was analyzed in separate model and data from ages 10 and 18 years were 
analyzed in the same model. The following variables also had data at both years: age at 
follow up, BMI, and height. The full mixed model was controlled for the confounders 
mentioned above.  An autoregressive covariance structure was used. Manual backward 
elimination of confounder applying the 10% rule was used to determine the most 
appropriate model. False discovery rate (FDR) was used to adjust for multiple testing 127. 
FDR was applied separately, once with tests involving LEPR and LEPROT SNPs only 
and another time looking only at the LEP SNPs.  
  
3.3 RESULTS 
Of the 1,373 children who followed up at age 10 years, n=981 and n=980, 
children had measures on FVC and FEV1, respectively. Of the 1,313 children who 
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followed up at age 18 years, FVC and FEV1 were collected on n=838 and n=839 
children, respectively (Table 3.2). Height, BMI, FVC, and FEV1 all increased from ages 
10 to 18 years. Boys and girls had about the same average FVC and FEV1 at age 10 years 
(FVC~2.3 L, FEV1~2.0 L) but at age 18, lung function in boys nearly doubled while that 
in girls increased by half the amount (data not shown). At age 18, FVC in boys increased 
by 3 L (STD: 0.5) and increased by 1.7 L (STD=0.4) in girls. Similarly, FEV1 in boys 
increased by 2.5 L (STD: 0.4) while only increasing by 1.5 L (STD: 0.4) in girls 
(stratified data by sex not shown). The FEV1/FVC ratio was the same at both ages (Table 
3.2). About a quarter of the children (25.25%) were exposed in utero to maternal 
smoking, almost half of the children in the study (45.46%) reported ever having smoked; 
9.3 % of mothers and 10.3 % of fathers were reported to have asthma (Table 3.2).  
The four LEP SNPs that were examined in this study spanned the length of the 
leptin gene, with one in the promoter region (5’UTR), one in the gene’s intron, and two 
located in the 3’UTR. In our data, the first LEPROT SNP we have is in the intron region 
and is preceded by the LEPR 5’UTR rs3896318 SNP. Two more LEPROT SNPs are in 
the intron region, followed by four located in the flanking 3’UTR (Table 3.4). This is 
followed by three more LEPR SNPs that are in the promoter region of the gene, three in 
the codon region, and six in the intron region. The last LEPR SNP is in the 3’UTR region.  
Linkage disequilibrium analysis of the 14 LEPR and 7 LEPROT genes resulted in 
5 haplotype blocks and 5 SNPs that did not fit into any blocks (Figure 3.1). SNPs from 
the blocks were chosen based on what was used previously by our team 61 and the five 
individual SNPs were also considered. These ten SNPs included rs3806318, rs9436740, 
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rs9436301, rs17412175, rs6669354, rs7526141, rs12059300, rs1137101, rs3762274, and 
rs8179183 (Figure 3.1).   
After adjustment for multiple testing via FDR (p-value cut-off of 0.05) 127, linear 
mixed models indicated that three SNPs (rs6669354, rs1137101, rs3762274) were 
associated with lowered lung function in the repeated measurement analyses (Table 3.5). 
In the flanking 3’UTR region of the LEPROT SNP, those with the AC genotype of 
rs6669354 had 0.092 L lower FVC and 0.10 L lower FEV1 than those with the AA 
genotype (Adjusted P=0.015 for both tests, Table 3.5). Maternal smoking during 
pregnancy, whether the child ever smoked, birth weight, duration breastfeeding, and 
socioeconomic status did not confound the association. The LEPR SNPs rs1137101 and 
rs3762274 were associated with lower FEV1/FVC (Table 3.5). Whether the child smoked 
and breastfeeding duration were significant factors in the association between rs1137101 
and FEV1/FVC, while breastfeeding duration did not confound the association when 
considering the rs3762274 SNP (Table 3.5). None of the LEP SNPs were associated with 
FVC, FEV1, or FEV1/FVC (data not shown). 
Since sex was a significant confounder in all the models, we investigated 
interaction effects of sex and age of follow-up in the four significant models (Table 3.6). 
We found that in all the four models, there was a significant difference in the rate of 
change in lung function over time between girls and boys. Girls had a lesser increase in 
FVC, FEV1, and FEV1/FVC compared to boys (Table 3.6). For example, when 
considering rs6669354, girls had an increase in FVC that was -0.090 liters lower than the 
increase in FVC in boys. Sex did not mediate the association between any of the LEP 
SNPs and any of the lung function values (data not shown). In addition, the child ever 
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smoking or duration of breastfeeding also did not mediate the relationship between any of 
the LEP SNPs and any of the lung function values. 
 
3.4 DISCUSSION 
 The findings of this study suggest that single nucleotide polymorphisms (SNPs) 
of the leptin receptor play an important role in the body’s lung volume and in airway 
obstruction. Our findings agree with Hansel et al that found an association between LEPR 
SNPs and lung function decline 54, although they tested different SNPs. Our findings, 
however, are not in agreement with van den Borst et al 52 who looked at one of our same 
significant LEPR SNPs (rs1137101) and found no association with FEV1 or FVC. 
LEPROT and LEPR SNPs were associated with decreased lung function in boys and girls 
between ages 10 and 18 years. Lung function increased in both boys and girls with 
increased age; however, those with certain genotypes experienced less of an increase. For 
example, 207 children with the AC genotype of rs6669354 (19.5% for the SNP) had 
lower FVC and FEV1 than those with the AA genotype (Tables 3.4 and 3.5).  Likewise, 
347 (30.2%) children with AA genotype of rs1137101 and 421 (37.8%) children with AA 
genotype of rs3762274 had lower FEV1/FVC than those with the AG genotype.  
Furthermore, girls experienced significantly less increase in all lung function measures 
when compared to boys. None of the LEP SNPs were associated with lung function. 
 The leptin receptor protein is known to exist in six isoforms, LEPRa, LEPRb, 
LEPRc, LEPRd, LEPRe, and LEPRf. LEPRb is the 156 is the long form of the leptin 
receptor and is the one that the leptin protein attaches to and starts the JAK/STAT 
pathway that is involved in inflammation. It is not possible while looking at just LEPR 
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SNPs, to determine what splicing will occur, subsequently resulting in the different forms 
of the leptin receptor. For this reason, it would be valuable also to consider the leptin 
receptor protein.  
 There were no differences between the whole population cohort and the sample 
used in this analysis when considering the confounding variables (Table 3.3). However, 
there was a significant difference in missing data in the follow-up data for socioeconomic 
status, maternal smoking during pregnancy, and whether the child ever smoked. The 
proportion of missing data is lower in the samples with lung function, hence it is unlikely 
that a non-response bias affected the analyses of the data. The significant difference in 
the missing data suggests that those who did not provide information on socioeconomic 
status, maternal smoking during pregnancy, and whether the child ever smoked, were 
also less likely to follow up with their lung function measurements later in the study. 
FVC and FEV1 were collected under standard clinic conditions at ages 10 and 18-year 
visits, reducing the possibility for information bias. Due to the link between leptin and 
body mass index (BMI), we tested that BMI at ages 10 and 18 and the SNPs were not 
associated (Appendix A).  
 Understanding leptin’s role in the body is difficult because the protein is involved 
in both the pro-inflammatory and anti-inflammatory response.  Leptin up-regulates the 
expression of pro-inflammatory cytokines, such as TNF-α, IL-6, and IL-12 86,157, but also 
increases chemotaxis and natural killer cell functions 83. The observed association 
between mutations at the coding and intron region of the LEPR gene being associated 
with lower FEV1/FVC, suggest that these SNPs may affect the body’s pro-inflammatory 
response. Leptin has to bind to its receptor in order to start the chain of events that lead 
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the body’s secretion of various cytokines 134,135,137,138,158. An illuminating step would be 
to explore associations between these LEPR and LEPROT SNPs and the cytokines in the 
JAK-STAT pathway.  
 
3.5 CONCLUSION 
Our findings show that the LEPROT SNP rs6669354 and the LEPR SNPs 
rs1137101 and rs3762274 are associated with decreased lung function and that between 
the ages of 10 and 18 years, girls experience a smaller increase in lung function that boys. 
However, no difference was found between the SNP-lung function association between 
boys and girls. This shows the differences observed between the sexes in leptin and lung 
function between the ages of 10 and 18 may not be explained on the genetic level. It 
would be valuable to look directly at protein leptin receptor. It could also be important to 
consider associated between these LEPROT and LEPR SNPs and cytokines involved in 
the JAK/STAT pathway. Lastly, in our data LEP SNPs were not found to be associated 







Table 3.1. Literature review of associations between SNPs in this study and lung function 
 
LEPR SNP Article Findings 
rs8179183 
Hansel, N.N., et al., Leptin receptor polymorphisms and lung function 
decline in COPD. Eur Respir J, 2009. 34(1): p. 103-10. 
Associated with reduced FEV1. 
Loos, R.J., et al., Polymorphisms in the leptin and leptin receptor genes 
in relation to resting metabolic rate and respiratory quotient in the 
Quebec Family Study. Int J Obes (Lond), 2006. 30(1): p. 183-90. 
Homozygote had a lower respiratory 
quotient than the other genotypes. 
rs1137100 
van den Borst, B., et al., Genetics of maximally attained lung function: 
a role for leptin? Respir Med, 2012. 106(2): p. 235-42. 
No association found with FEV1 or FVC. 
Hansel, N.N., et al., Leptin receptor polymorphisms and lung function 
decline in COPD. Eur Respir J, 2009. 34(1): p. 103-10. 
Associated with reduced FEV1. 
Loos, R.J., et al., Polymorphisms in the leptin and leptin receptor genes 
in relation to resting metabolic rate and respiratory quotient in the 
Quebec Family Study. Int J Obes (Lond), 2006. 30(1): p. 183-90. 
Homozygote had a lower respiratory 
quotient than the other genotypes. 
rs1137101 van den Borst, B., et al., Genetics of maximally attained lung function: 
a role for leptin? Respir Med, 2012. 106(2): p. 235-42. 
No association found with FEV1 or FVC. 
rs1782754 Hansel, N.N., et al., Leptin receptor polymorphisms and lung function 
decline in COPD. Eur Respir J, 2009. 34(1): p. 103-10. 
Associated with reduced FEV1 in COPD 
patients. 
rs3828934 Hansel, N.N., et al., Leptin receptor polymorphisms and lung function 
decline in COPD. Eur Respir J, 2009. 34(1): p. 103-10. 





Table 3.2. Population Characteristics 
 
Variable N Mean Median p5, p95 
Birth weight (kg) 1511 3.39 3.41 2.57, 4.20 
Duration breastfeeding (weeks) 1345 14.28 8.00 0.00, 40.00 
FVC at age 10 (L) 981 2.29 2.28 1.76, 2.88 
FVC at age 18 (L) 838 4.61 4.47 3.22, 6.28 
FEV1 at age 10 (L) 980 2.03 2.01 1.58, 2.56 
FEV1 at age 18 (L) 839 4.01 3.91 2.85, 5.41 
FEV1/FVC at age 10 980 0.89 0.89 0.79, 0.97 
FEV1/FVC at age 18 839 0.87 0.88 0.75, 0.98 
Height at age 10 (cm) 1043 138.93 138.70 129.10, 149.50 
Height at age 18 (cm) 994 171.21 171.00 156.50, 187.00 
BMI at age 10 (kg/m2) 1043 18.11 17.35 14.71, 23.95 
BMI at age 18 (kg/m2) 964 23.19 22.15 18.20, 32.14 
Age at 10-year follow up (years) 1536 10.02 10.00 9.57, 10.55 
Age at 18-year follow up (years) 1255 17.91 17.72 17.17, 19.13 
  N  %  
Sex                                                   Male 786 51.17  
 Female 750 48.83  
Socio-economic status                     High 111 8.18  
 Mid 1037 76.42  
 Low 209 15.40  
Parental asthma status                  None 1208 80.37  
 Father 140 9.31  
 Mother 155 10.31  
In utero smoking exposure                Yes 384 25.25  





Table 3.3 Whole population cohort vs. sample with lung function data at ages 10 or 18  
*This significant difference is due to differences in frequency of missing data for these 





FEV1 data at 
ages 10 or 18 
years 
 
Variable N, Mean; STD N, Mean, STD P-Value 
Birth weight (kg) 1511, 3.39; 0.54 1102, 3.41, 0.51 0.34 
Missing 25 18  
Duration breastfeeding 
(weeks) 
1345, 14.28; 14.8 1031, 15.08, 
14.96 
0.19  
Missing 191 89  
Height at age 10 (cm) 1043, 138.93; 6.18 1025, 138.90, 
6.16 
1.00 
Missing 493 95  
Height at age 18 (cm) 994, 171.21; 9.45 918, 170.98, 
9.30 
1.00 
Missing 542 202  
BMI at age 10 (kg/m2) 1043, 18.11; 2.98 1025, 18.12, 
2.98 
1.00 
Missing 493 95  
BMI at age 18 (kg/m2) 964, 23.19; 4.33 896, 23.21, 4,33 0.92 
Missing 572 224  
  N (%) N(%)  
Sex                                                   Male 786 (51.17) 557 (49.73)  0.48 
 Female 750 (48.83) 563 (50.27) 
Socio-economic status                     High 111 (7.23) 85 (7.59) <.0000001* 
 Mid 1037 
(67.51) 
849 (75.80) 
 Low 209 (13.61) 160 (14.29) 
 Missing 179 (11.65) 26 (2.32) 
Parental asthma status                  None 1208 
(78.65) 
892 (79.64) 0.37 
 Father 140 (9.11) 104 (9.20) 
 Mother 155 (10.09) 110 (9.82) 
 Missing 33 (2.15) 15 (1.34) 
In utero smoking 
exposure                
Yes 384 (25.00) 253 (22.59) 0.05* 
 Missing 15 (0.98) 4 (0.36)  
Child ever smoked                             Yes 581 (37.83) 449 (40.09) <.0000001* 
 Missing 258 (16.80) 93 (8.30) 
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Table 3.4: LEP, LEPR, and LEPROT SNP characteristics  
 
Gene SNP Genotype N (%) Location Coordinate 
LEP rs10249476 
AA 156 (13.55) 
Flanking_5UTR 128236973 AC 542 (47.09) 
CC 453 (39.36) 
LEP rs11763517 
AA 293 (25.46) 
Intron  128250009 AG 569 (49.44) 
GG 289 (25.11) 
LEP rs4731429 
AA 238 (20.66) 
Flanking_3UTR  128263486 AG 582 (50.52) 
GG 332 (28.82) 
LEP rs10954176 
AA 338 (29.57) 
Flanking_3UTR  128267266 AG 534 (46.72) 
GG 271 (23.71) 
LEPR rs3806318 
AA 580 (50.88) 
Flanking 5’UTR 65885357 AG 465 (40.79) 
GG 95 (8.33) 
LEPROT rs9436738 
AA 10 (0.86) 
Intron 65888560 AG 241 (20.81) 
GG 907 (78.32) 
LEPROT rs9436740 
AA 101 (8.83) 
Intron 65891901 AT 446 (38.99) 
TT 597 (52.19) 
LEPROT rs9436301 
AA 658 (57.17) 
Intron 65895927 AG 431 (37.45) 
GG 62 (5.39) 
LEPROT rs17412175 
AA 243 (21.11) 
Flanking 3’UTR 65904886 AT 560 (48.65) 
TT 348 (30.23) 
LEPROT rs9436747 
AA 175 (15.07) 
Flanking 3’UTR 65911607 AG 512 (44.10) 
GG 474 (40.83) 
LEPROT rs9436748 
AA 214 (18.71) 
Flanking 3’UTR 65911672 AC 556 (48.60) 
CC 374 (32.69) 
LEPROT rs6669354 
AA 836 (78.65) 
Flanking 3’UTR 65925349 AC 207 (19.47) 
CC 20 (1.88) 
LEPR rs7526141 
AA 256 (22.20) 
Flanking 5’UTR 65975275 
AG 556 (48.22) 
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GG 341 (29.58) 
LEPR rs1171275 
AA 32 (2.78) 
Flanking 5’UTR 65982633 AG 334 (29.04) 
GG 784 (68.17) 
LEPR rs1782754 
AA 590 (50.82) 
Flanking 5’UTR 65993348 AG 473 (40.74) 
GG 98 (8.44) 
LEPR rs1137100 
AA 592 (51.30) 
Coding 66036441 AG 465 (40.29) 
GG 97 (8.41) 
LEPR rs3790424 
AA 580 (50.70) 
Intron 66044013 AG 457 (39.95) 
GG 107 (9.35) 
LEPR rs10493380 
AA 791 (69.45) 
Intron 66046117 AC 317 (27.83) 
CC 31 (2.72) 
LEPR rs12059300 
AA 37 (3.20) 
Intron 66047072 AG 378 (32.70) 
GG 741 (64.10) 
LEPR rs1137101 
AA 347 (30.15) 
Coding 66058513 AG 558 (48.48) 
GG 246 (21.37) 
LEPR rs3828034 
AA 777 (67.80) 
Intron 66062325 AG 330 (28.80) 
GG 39 (3.40) 
LEPR rs3762274 
AA 421 (37.83) 
Intron 66064113 AG 525 (47.17) 
GG 167 (15.00) 
LEPR rs8179183 
CC 37 (3.23) 
Coding 66075952 CG 320 (27.97) 
GG 787 (68.79) 
LEPR rs6678033 
AA 159 (13.96) 
Intron 66077624 AG 533 (46.80) 
GG 447 (39.24) 
LEPR rs17415296 
AA 38 (3.27) 
3’ UTR 66099013 AC 332 (28.55) 




Table 3.5. LEPR and LEPROT SNPs associated with lung function measures 
 
Associated with FVC (Liters) 






rs6669354a AC -0.092 0.028 
0.0010 0.01500  CC 0.16 0.097 
 AA REF REF 
Associated with FEV1 (Liters) 






rs6669354b AC -0.10 0.026 
0.0007 0.01500  CC -0.021 0.090 
 AA REF REF 
Associated with FEV1/FVC (Liters) 






rs1137101c AA -0.012 0.0046 
0.0055 0.04125  GG 0.0053 0.0051 
 AG REF REF 
rs3762274d AA -0.013 0.0042 
0.0024 0.02400  GG 0.0031 0.0057 
 AG REF REF 
a, b: Controlled for age at each follow up, sex, height at ages 10 and 18, and BMI at ages 
10 and 18. 
c: Controlled for age at each follow up, sex, whether the child ever smoked, height and 
BMI at ages 10 and 18, and the duration of breastfeeding. 
d: Controlled for age at each follow up, sex, whether the child ever smoked, and height 




Table 3.6. Interaction effect of sex and age of follow up on lung function measures 
 
 








 Associated with FVC (Liters) 





  CC vs 
AA 
0.18 0.093  
 Age at 
follow up 
(years) 
 0.15 0.0085 <0.0000001  
 Sex                   
Female vs. 
Male 




 -0.090 0.0045 <0.0000001 <0.0000001 
 Associated with FEV1 (Liters) 





  CC vs 
AA 
-0.0020 0.086  
 Age at 
follow up 
(years) 
 0.13 0.0077 <0.0000001  
 Sex                   
Female vs. 
Male 




 -0.078 0.0044 <0.0000001 <0.0000001 
 Associated with FEV1/FVC (Liters) 





  GG vs 
AG 
0.0053 0.0051  
 Age at 
follow up 
(years) 
 0.0032 0.0014 0.0483  
47 
 
 Sex                   
Female vs. 
Male 




 -0.0018 0.00077 0.0199 0.0199 





  GG vs 
AG 
0.0027 0.0057  
 Age at 
follow up 
(years) 
 0.0037 0.0014 0.0166  
 Sex                   
Female vs. 
Male 




 -0.0019 0.00075 0.0127 0.0199 
a, b: Also controlled for height at ages 10 and 18, and BMI at ages 10 and 18. 
c: Also controlled for whether the child ever smoked, height and BMI at ages 10 and 18, 
and the duration of breastfeeding. 













RESULTS II – MANUSCRIPT #2 
 
LEP SNPS AND DNA METHYLATION INFLUENCE SERUM LEPTIN LEVELS IN 
BOYS AND GIRLS: TWO-STAGE MODEL OF EPIGENETIC ANALYSIS2 
 
4.1 INTRODUCTION 
Leptin is a 16kDa pleiotropic cytokine that plays a role in many physiological 
processes in the body 159-162 and is intimately linked to the body’s host inflammatory 
response 132,133,163. The levels of circulating leptin in the body affect subsequent 
biological pathways. For example, with moderate leptin levels Th1/Th2/Treg cells are in 
equilibrium indicating an optimal immune response. However, when the body has low 
amounts of leptin (hypoleptinaemia), Th1 cells are impaired and Treg cells proliferate, 
leading to suppressed immune response and increased infections and disease 
susceptibility (such as tuberculosis, candida, and pneumonia). If the body has an excess 
of leptin (hyperleptinaemia), Treg cells are reduced and Th2 cells increase secretion of 
proinflammatory cytokines, which can influence obstructive lung diseases such as asthma 
5,22. It is therefore important to understand what factors can influence leptin levels in the 
body.  
Genetic variations in the leptin gene have been associated with protein leptin 
levels. Numerous candidate gene studies looking at single nucleotide polymorphisms 
                                                          
2 M. Yousefi, W. Karmaus, H. Zhang, M Torres, J Burch, E Schauberger. LEP SNPs and DNA methylation 
influence serum leptin levels in boys and girls: Two-Stage model of epigenetic analysis. To be submitted. 
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(SNPs) have detected associations between G-2548A (also known as rs7799039, located 
in the promoter region of the gene) and decreased leptin levels 164-169.  Conversely, 
Fourati et al found that two LEP SNPs in the promoter region of the gene (H1328084 and 
A19G) were associated with increased leptin levels 62. In a genome-wide meta-analysis, 
questions arose about the association of LEP SNPs with circulating leptin levels. The 
LEP SNP, rs10487505 (located in the intron region), was associated with decreased leptin 
levels, but was not associated with LEP messenger RNA expression in the omental or 
subcutaneous adipose tissue, liver, lymphocytes, or the brain. This suggested that other 
mechanisms may be at play in mediating the association between LEP SNPs and leptin 
levels 170. 
A possible such mediator (and effect modifier) could be DNA methylation of LEP 
gene, which may influence the expression of leptin protein. Few studies have looked at 
DNA methylation in the leptin gene and only one study has investigated the association 
between LEP DNA methylation and leptin protein levels. Hillemacher et al found that 
LEP DNA methylation in the promoter region of the gene was associated with increasing 
serum leptin levels in alcohol dependent patients who were going through withdrawal 68.  
Since the process of DNA methylation begins in utero, it is helpful to look at 
environmental exposures that occur during pregnancy. In a previous study using data 
from the Isle of Wight birth cohort study, the interaction between maternal smoking 
during pregnancy and leptin receptor (LEPR) SNPs was associated with DNA 
methylation in the offspring 61. We followed the same analytical steps using LEP SNPs 
and LEP DNA methylation levels. Specifically, we used data from the Isle of Wight Birth 
Cohort Study to investigate a two-stage explanatory model: First, LEP SNPs have the 
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potential to constitute methylation quantitative trait loci (methQTLs), i.e., specific 
genotypes of SNPs may influence the susceptibility of specific gene loci to change the 
level of DNA-methylation. In addition, this susceptibility may be modified by 
environmental exposures.  Thus, SNPs may interact, for instance, with in utero smoking 
exposure. Second, we tested to see if the DNA methylation sites (CpG sites: locations on 
a DNA sequence where hydrogen groups are replaced with a methyl group) that are 
identified as being related to methQTLs were associated with serum leptin concentrations 
at age 18 years. We also examined whether the methQTLs findings could be replicated in 
the F2 population of the three generation Isle of Wight birth cohort. This was the first 




4.2.1 STUDY POPULATION AND CHARACTERISTICS 
4.2.1A F1 POPULATION 
Between January 1989 and February 1990, 1536 F1-children born on the Isle of 
Wight (IOW), UK were recruited and interviewed with 1456 available for further follow-
up in a longitudinal study. The local research ethics committee approved the study and 
informed written parental consent was obtained from all participants at recruitment and 
subsequently at each follow-up. The IOW birth cohort has been described in detail 
elsewhere 61,152. Briefly, upon delivery, birth weight was measured and data from birth 
records and questionnaires were collected, including information on maternal smoking 
during pregnancy. Children were followed up at the ages of 1 (n=1167, 80.2%), 2 
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(n=1174, 80.6%), 4 (n=1218, 83.7%), 10 (n=1373, 94.3%) and 18 years (n=1313, 
90.2%). Data was collected at each follow up time via interviews and examinations. 
When a visit was not possible, a telephone questionnaire was completed or a postal 
questionnaire was sent. Information on maternal smoking during pregnancy was obtained 
from mothers at the time of birth.  
Leptin concentrations were obtained from blood samples collected from F1-
children at age 18 years. Aliquots of blood serum isolated from the blood samples were 
used in enzyme-linked immunosorbent assays from Biokit, S.A. (Barcelona, Spain). The 
assays were conducted according to the manufacturer’s kit instructions. Each sample, 
including standards and the blank, was assayed in duplicate. 
DNA was extracted from blood or saliva samples from cohort subjects (n=1,211). 
Details of the procedure have been described elsewhere 61,171. Four LEP SNPs 
(rs4731429, rs10249476 rs10954176, and rs11763517) were genotyped in the F1 
population. For measuring methylation levels, DNA was extracted from whole blood 
collected at age 18 years from 245 female offspring and 125 male offspring.  DNA was 
extracted from peripheral blood samples collected from the F1 generation at age 18, 
during pregnancy, and from cord blood of F2 at birth. DNA methylation levels were 
measured using the Illumina 450K platform and quantified using β values that present the 
proportion of methylated (M) over the sum of methylated and unmethylated (U) allele 
intensities (β=M/ [c+M+U]), where c is a constant to prevent zero in the denominator 172. 
The β values were employed as predictors of asthma or wheezing; however, for 
methylation analysis we used M-values (logit-transformed β values) as the response 




4.2.1B F2 POPULATION 
These F1 participants themselves became pregnant or fathered a child, who was 
then enrolled in a follow-up study. Cord blood was collected from the F2-offspring for 
DNA methylation; however, cord blood samples could not be collected in all deliveries.  
SNPs in the F2 generation were genotyped on Illumina's HumanOmniExpressExome 
beadchip (v1.2) for more than 960k loci. Arrays were processed at the Wellcome Trust 
Centre for Human Genetics (Oxford, UK). Genotypes were extracted from image data 
using GenomeStudio software (Illumina). SNPs located in or near IL1RL1 were 




4.2.2 STATISTICAL ANALYSIS 
4.2.2A F1 POPULATION 
 Haplotype analysis performed on the LEP SNPs in the F1 generation of this 
cohort in a previous study by Mukherjee et al 128 showed that two of the SNPs present in 
the F1 generation data had been in LD with each other: rs10249476 and rs11763517. 
Therefore, in our analysis involving LEP SNPs in the F1 generation we included: 
rs11763517, rs4731429, and rs10954176. 
After cleaning the DNA-M data, beta (β) values were presented as the proportion 
of methylated (M) over methylated (M) and unmethylated (U) sites (β=M/[c+M+U], with 
c being constant to prevent dividing by zero) were used to estimate the effect of DNA-M 
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[51]. M-values were then calculated using the logit-transformed β values (log2β /(1-β )). 
The M-values of the methylation of seven CpG sites (six at the start and one at the end of 
the LEP gene) were analyzed in this study.  
In Stage 1, to identify methQTLs modified by gestational maternal smoking, 
modeling was performed by using LEP SNPs and their interaction with in utero smoking 
exposure to predict the methylation of LEP CpG sites. Each CpG (M-values) was 
modeled against rs11763517, rs4731429, and rs10954176, with each SNP interacting 
with in utero smoking exposure. In addition, all models were controlled for cell-
composition to ensure that we were indeed observing associations with DNA methylation 
un-confounded by the proportion of these cells. We controlled for levels of the following 
cells: b cells, granulocytes, monocytes, natural killer cells, eosinophils, and CD4 T-cells. 
These cell counts were obtained from breast cancer patients from the Winship Cancer 
Institute 129, 61 subjects at baseline and 39 subjects at six-month-follow-up. We followed 
the method used by Kaushal et al 130 where 484,489 CpG sites were tested against cell 
types. The most parsimonious model was determined via backward elimination using the 
10% rule, first by removing interaction terms followed by individual SNPs. False 
discovery rate was used to adjust for multiple testing.  
Stage 2: Next, the selected CpG sites (M-values) were tested on whether they 
modified the association that LEP SNPs had with leptin serum concentrations at age 18. 
In this step, our focus was on the interaction effects and false discovery rate was applied 
to correct for multiple testing among the tests for interaction effects between CpG sites 
and genetic variants. For both sets of statistical analyses, the GLM procedure was used in 
SAS 9.4 (SAS, Gary, NC, USA). In addition, because leptin levels vary greatly between 
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boys and girls following puberty, all models initially controlled for sex as well. As the 
proportion of girls in the subsample with DNA-methylation was higher than the 
proportion of, the analyses were weighted for sex. Since the same SNP (rs4731429) that 
was a methQTL for cg00840332 was also a genetic modifier in the association between 
DNA-M and leptin levels,  we calculated the residuals from the association between 
rs4731429  and cg00840332 using linear regression analyses. These residuals are no 
longer affected by rs4731429 and can be used as independent variable to test interaction. 
The residuals were then used in testing direct and interactive effects of  DNA-M on leptin 
levels. 
4.2.2B F2 POPULATION 
The methQTL analysis was replicated in the F2 population. Eighteen LEP SNPs 
were genotyped in the F2 population but only 5 SNPs (rs2167270, rs2278815, 
rs11760956, rs11763517, rs12706832) proved to have polymorphisms (the others were 
monomorph, with all or almost all the population having one of the possible genotypes). 
Haplotype analysis using Haploview software 125 revealed that SNPs rs2278815 and 
rs12706832 were in LD with each other while rs11763517 and rs11760956 were in LD 
with each other (Figure 4.1). Therefore, the methQTL analysis included the following 
SNPs interacting with in utero smoking exposure predicting DNA methylation levels: 
rs2278815, rs11763517, and rs2167270. While the SNPs in the F1 population were 
collected via selected probes, a commercial genome wide product was used in the F2 
population. This led to the following SNPs, rs2167270, rs2278815, rs11760956, and 
rs12706832 not being identical with the SNPs identified in the F1 population. Hence, in 
order to see if the findings in the F2 population are based on closely related SNPs, we 
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generated a second LD plot using the International Haplotype Map (HapMap) project 
data from the Central European University database 131 (Figure 4.2).  
 
4.3 RESULTS 
4.3.1 F1 GENERATION COHORT 
Of the 1,152 participants from the whole birth cohort who had SNP data, 370 also 
had DNA methylation data. There was no difference in the frequency of LEP SNP alleles 
between the sub and whole populations (Table 4.1). There was also no difference in the 
percentage of participants who were exposed to in utero smoking or in leptin levels at age 
18. Because of interest of the parent study in the female line, more female participants 
with DNA-methylations were selected for DNA-methylation analysis (66.2%). Girls had 
higher leptin levels at age 18 (19.2 ng/mL) than boys (4.0 ng/mL, Table 4.1).  
The four LEP SNPs in the F1 generation spanned the length of the leptin gene, 
with one SNP in the flanking 5’UTR region, one in the intron region, and two in the 
Flanking 3’UTR region (Table 4.3). LEP SNPs rs10249476 and rs11753517 were in 
linkage disequilibrium with each other 128. Therefore, the models predicting DNA 
methylation levels used the following SNPs: rs11763517, rs4731429, and rs10954176. 
There were seven DNA methylation sites that were examined in the F1 
generation, which were located at the start and end of the leptin gene, but none in the 
middle of the gene (Table 4.4).  All but two of the CpG sites presented high DNA 
methylation levels (β-levels >0.90) while cg00840332 and cg00666422 showed low (β-
levels: average 0.16) and medium (average 0.46) methylation, respectively (Table 4.4).  
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In utero smoking exposure did not play a role in the association between LEP SNPs and 
LEP DNA methylation levels.   
Three CpG sites were observed to have methylation quantitative trait loci 
(methQTL) (Table 4.5). Those with the AA and AG alleles of the rs4731429 SNP were 
associated with a higher proportion of DNA methylation at the cg00666422 and 
cg00840332 sites than those with the GG allele. Both the cg00840332 and cg00666422 
methylation sites are located at the start of the LEP gene (TS200 CpG island and 5’UTR 
region respectively, Table 4.4) while the rs4731429 SNP is located at the 3’UTR region 
of the gene (Table 4.3a). Both of these methylation sites are also in cis association with 
rs4731429 since they are less than 1Mb from each other 82, Tables 4.2 and 4.3. LEP SNP 
rs4731429 also acted as a methQTL for cg24862443 (located at 3’UTR, Table 4.4), but 
the association is in the opposite direction: those with the AA and AG genotype of the 
SNP are associated with decreased proportion of methylation at that CpG site. The same 
direction of association was observed for rs11763157, which was also a methQTL for 
cg24862448. Sex only played a role in the cg00666422 methylation site. Boys had 0.17 
higher proportion of methylation (β-levels) than girls at the cg00666422 methylation site 
(Table 4.5). Because of the higher proportion of girls than boys in this subsample, sex 
was weighted in the analysis.  
One CpG site associated with a methQTL, cg00840332, was associated with 
leptin levels at age 18 years. This association was modified by rs4731429, which was the 
same SNPs that was a methQTL for the cg00840332 CpG site. Therefore, we calculated 
the residuals from the association between rs4731429 and cg00840332, and used those 
residuals in place of the cg0040332 in the model predicting leptin levels at age 18 (Table 
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4.7). Among those with the AA genotype of the rs4731429 and rs11763517 SNPs, 
increased methylation at cg00840332 was associated with decreased protein leptin levels 
by 20.4ng/mL and 16.4 ng/mL respectively (Table 4.7). 
4.3.2 REPLICATION ANALYSIS OF METHQTLS IN F2 POPULATION COHORT 
Regarding the 419 children enrolled thus far in the F2 population cohort, cord 
blood samples could not be collected from all children. Of the F2-children 139 also had 
SNP data, and 125 people had SNP and DNA methylation data. There was no difference 
in LEP SNP frequencies, sex, and in utero smoking exposure between the whole 
population cohort and the children who had SNP data (Appendix B). There was also no 
difference between the population with only SNP data and the population with SNP and 
DNA methylation data (Appendix B). After removing monomorphic genetic markers (no 
genetic polymorphisms), there were 5 LEP SNPs in the F2 population, with most of the 
children having the heterozygous genotypes (Table 4.2). The SNPs in the F2 cohort 
consisted of one in the exon region and the rest in the intron region of the gene (Table 
4.3). Of these 5 SNPs, rs2278815 and rs1276832 were in linkage disequilibrium with 
each other, rs11763517 and rs11760956 also were in linkage disequilibrium, (Figure 4.1). 
Even though only one of the LEP SNPs (rs11763517) in the F2 generation was the same 
as those analyzed in the F1 generation, other F2 and F1 SNPs were in linkage 
disequilibrium with each other (Figure 4.2). Namely, rs4731429 and rs11760956 were in 
the same haplotype block (Figure 4.2). Therefore, we could test whether we could 
replicate the methQTL results found in the F1-generation. The results show that those 
with the AA an AG genotypes of rs11760956 had a higher proportion of methylation at 
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cg00840332 than those with the GG genotype. This mirrors the findings of rs4731429 
being a methQTL for the same CpG site in the F1 population. 
 
4.4 DISCUSSION 
 First, our findings show an association between LEP SNPs and DNA-methylation 
in the F1-generation that could (partially) be replicated in the F2-generation. Those with 
the AA and AG genotypes of the rs4731429 SNP were more susceptible to DNA 
methylation at the cg00666422 and cg00840332 sites of the leptin gene (promoter regions 
of the gene). Conversely, those with the AA and AG genotypes of the rs4731429 were 
less susceptible to DNA methylation at the 3’UTR region of the gene, CpG site 
cg24862443 (Table 4.5). The findings at the cg00840332 CpG site were replicated in the 
subsequent generation (Table 4.6).  As DNA methylation increased at the cg00840332 
site, those with AA genotype of the rs11763517 SNP had lower leptin levels at age 18 
(Table 4.7). Second, our results show that associations between genetic polymorphisms 
and protein leptin levels are modified by LEP DNA methylation.  The F2 population did 
not have data on leptin levels, so the second part of the analysis could not be replicated in 
the subsequent generation. When comparing models of SNPs and CPG sites predicting 
protein leptin levels at age 18, SNPs and proportion of methylation indicate the same 
level of fit (R2=0.17) while the SNP-CPG interaction model shows a slightly stronger fit 
(R2=0.20). 
 It is unlikely that selection bias occurred in this study because the 370 participants 
in the F1 cohort and the 125 participants in the F2 cohort were selected due to study 
interests and do not deviate from their respective whole populations. For instance, there 
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were no differences between the frequencies of LEP SNPs between the sample and whole 
populations in both the F1 and F2 generations. There were also no differences in the 
proportion of people who were exposed to in utero smoking. Using the Infinium Human 
Methylation 450 array in the collection of DNA methylation data reduces the possibility 
of information bias because it has strong reproducibility and validity 120,121.  
 As expected, leptin levels were higher in girls than boys at age 18 years (Table 
4.1). However, this difference was not overwhelmingly reflected in DNA methylation 
levels. We did not see a significant association when testing the interaction of SNPs and 
sex on DNA methylation. Only one of the models for methQTL analysis showed that sex 
had a significant effect on the association between LEP SNPs and LEP DNA 
methylation: girls had lower DNA methylation at cg00840332 than boys. Hence, sex was 
a confounder in the association between LEP DNA methylation and protein leptin levels, 
but this association was not modified by sex.  The investigated LEP SNPs are likely to be 
representative of the leptin gene since they spanned the length of the gene (Table 4.3a) 
and were in linkage disequilibrium with SNP data used in the International HapMap 
project (Figure 4.2). However, the CpG sites used were mostly from the promotor region 
of the region, with only one site at the 3’UTR region and no sites from coding on intron 
regions of the gene (Table 4.4). It would be helpful for subsequent studies to investigate 
the effects of DNA methylation on more regions of the LEP gene.  
 
4.5 CONCLUSION 
 This study suggests that genetic variants of the LEP gene alter LEP DNA 
methylation patterns in two consecutive generations, and that these methylation patterns 
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in turn alter protein leptin levels in the F1 generation.  Our findings show that SNPs and 
DNA-M equally explain the variations in protein leptin levels but do not explain the 
difference in leptin levels between boys and girls. When leptin binds to the leptin 
receptor, it activates the Janus Kinas 2/Signal transducer and activator of transcription 
(JAK2/STAT) pathway that leads to the release of cytokines involved in the body’s 
immune response. A next step would be to investigate if there are other genes involved in 
the JAK/STAT pathway and in protein leptin levels that could explain the differences 






Table 4.1. Population characteristics for F1 generation cohort 
   
Sub population with DNA 
methylation data 
N=370 




SNP Genotype N (%) N (%)  
rs4731429 AA 76 (22.1) 238 (20.7) 
0.50  AG 174 (50.6) 582 (50.5) 
 GG 94 (27.3) 332 (28.8) 
rs10249476 AA 49 (14.2) 156 (13.6) 
0.19  AC 177 (51.3) 542 (47.1) 
 CC 119 (34.5) 453 (39.4) 
rs10954176 AA 93 (27.11) 338 (29.6) 
0.50  AG 164 (47.81) 534 (46.7) 
 GG 86 (25.07) 271 (23.7) 
rs11763517 AA 76 (21.9) 293 (25.5) 
0.25  AG 179 (51.6) 569 (49.4) 
 GG 92 (26.5) 289 (25.1) 
Variable N (Mean, Median; 5, 95%) N (Mean, Median; 5, 95%) P-Value 
Sex                                           Male 125 (33.8) 577 (50.1) <.0000001 
Female 245 (66.2) 575 (49.9) 
In utero smoking exposure (Yes) 75 (20.4) 266 (23.2) 0.26 
Leptin at age 18 in boys (ng/mL) 120 (4.0, 1.2; 0.40, 16.0) 270 (4.0, 1.2; 0.40, 14.0)  




Table 4.2. Population characteristics for F2 generation cohort 
Sub population with SNP and DNA methylation data 
N=125 
SNP Genotype N (%) 
rs2167270 AA 9 (7.2) 
 AG 61 (48.8) 
 GG 55 (44.0) 
rs2278815 AA 45 (36.0) 
 AG 62 (49.6) 
 GG 18(14.4) 
rs11760956 AA 9 (7.2) 
 AG 63 (50.4) 
 GG 53 (42.4) 
rs11763517 AA 34 (27.2) 
 AG 64 (51.2) 
 GG 27 (21.6) 
rs12706832 
 
AA 18 (14.4) 
 AG 62 (49.6) 
 GG 45 (36.0) 
Variable N (%) 
Sex                                           Male 64 (51.2) 
Female 61 (48.8) 
In utero smoking exposure          No 77 (64.2) 








Table 4.3. Location of LEP SNPs in F1 and F2 generation cohorts 
F1 generation F2 generation 
SNP  Location Chromosome: Coordinate SNP Location Chromosome: Coordinate 
rs10249476 Flanking 5’UTR 7: 127877026 rs2167270 Exon 7: 127881349 
rs11763517 Intron 7: 127890062 rs2278815 Intron 7: 127881851 
rs4731429 Flanking 3’UTR 7: 127903539 rs12706832 Intron 7: 127887139 
rs10954176 Flanking 3’UTR 7: 127907319 rs11763517 Intron 7: 127890062 
   rs11760956 Intron 7: 127891087 








Table 4.4. Distribution of DNA methylation of CPG sites on the LEP gene for F1 and F2 generations (β methylation levels) 
   F1 generation F2 generation 
CpG site Location 
Chromosome: 
Coordinate 
N Mean 5% 95% N Mean 5% 95% 
cg14734794 TSS1500 7:127879921 370 0.96 0.95 0.97 125 0.92 0.90 0.95 
cg00840332 TSS200 7:127881270 370 0.16 0.10 0.23 125 0.084 0.049 0.13 
cg00666422 5'UTR 7:127881441 370 0.46 0.37 0.54 125 0.44 0.38 0.50 
cg12083122 5'UTR 7:127883820 370 0.95 0.94 0.97 125 0.91 0.89 0.93 
cg25435800 5'UTR 7:127890194 370 0.93 0.90 0.96 125 0.89 0.85 0.93 
cg25730670 5'UTR 7:127891366 370 0.95 0.93 0.96 125 0.90 0.87 0.92 
cg24862443 3'UTR 7:127896860 370 0.94 0.92 0.95 125 0.88 0.86 0.90 









Table 4.5. Methylation quantitative trait loci analysis for F1 generation cohort (M-values) 
Variable  Estimate STD 






Predicting methylation site: cg00666422* 
rs11763517 (AA vs GG) -0.12 0.06 0.036 
0.10 0.10 
 (AG vs GG) -0.05 0.05 0.24 
rs4731429 (AA vs GG) 0.13 0.06 0.03 
0.005 0.006 
 (AG vs GG) 0.14 0.04 0.001 
Predicting methylation site: cg00840332 
rs4731429 (AA vs GG) 0.31 0.07 0.000002 
0.00001 0.00005 
 (AG vs GG) 0.15 0.06 0.006 
Sex Male vs. Female 0.17 0.06 0.01 0.007 N/A 
Predicting methylation site: cg24862443* 
rs11763517 (AA vs GG) -0.14 0.04 0.001 
0.005 0.006 
 (AG vs GG) -0.05 0.03 0.095 
rs4731429 (AA vs GG) -0.14 0.04 0.0014 
0.0046 0.006 
 (AG vs GG) -0.08 0.03 0.01 
*Models controlled for concentrations of the following cells: b cells, granulocytes, monocytes, natural killer cells,  







Table 4.6. Methylation quantitative trait loci analysis for F2 generation cohort (M-values) 
Variable  Estimate STD 




Predicting methylation site: cg00666422* 
rs11760956 (AA vs GG) 0.20 0.08 0.01 
0.03 
 (AG vs GG) 0.13 0.06 0.02 
rs2167270 (AA vs GG) 0.23 0.10 0.02 
0.006 
 (AG vs GG) 0.17 0.05 0.002 
Predicting methylation site: cg00840332* 
rs11760956 (AA vs GG) 0.51 0.16 0.0019 
0.0002 
 (AG vs GG) 0.30 0.08 0.0004 
*Models controlled concentrations of the following cells: b cells, granulocytes, monocytes, natural killer cells, eosinophils, and CD4t 
cells. 
Note rs11760956 in the F2-generation and rs4731429 in the F1 generation are in linkage disequilibrium, presenting the same 








Table 4.7. LEP DNA methylation predicting protein leptin levels (ng/mL) at age 18 in the F1 generation* 






Cg00840332** 11.3 8.3 0.18 0.016 N/A 
rs11763517                                          AA vs GG 7.7 3.7 0.04 0.11 N/A 
AG vs GG 3.2 2.8 0.25 
Cg00840332** rs11763517                   AA vs GG -16.4 7.8 0.037 
0.01 0.02 
AG vs GG -0.20 6.8 0.98 
rs4731429                                            AA vs GG 7.7 3.6 0.03 0.07 N/A 
AG vs GG 1.4 2.7 0.6 
Cg00840332** rs4731429                     AA vs GG -20.4 8.9 0.02 
0.028 0.028 
AG vs GG -14.7 5.9 0.01 
Sex                                              Male vs. Female  -17.5 2.4 <.0000001 <.0000001 N/A 
**This model is also controlled for the following cells: b cells, granulocytes, monocytes, natural killer cells,  
eosinophils, and CD4t cells.  
















RESULTS III - MANUSCRIPT #3 
 
LEPTIN ASSOCIATED WITH LUNG FUNCTION INDEPENDENT  
OF BODY MASS INDEX3 
 
5.1 INTRODUCTION 
Historically leptin has been identified as regulator of appetite and energy expenditure 
and is known for its relationship with obesity 1. However, over time it has been 
established as a pleiotropic hormone that is responsible for many processes in the body 3-
20,22,24. Leptin was initially believed to be secreted only from adipose tissue, but in 
consequent years it has also been detected in lower concentrations in peripheral lung 
tissue in mice (bronchial epithelial cells, alveolar type II pneumocytes, and lung 
macrophages) 174. Leptin is also thought to play a key role in lung maturation and to be a 
stimulant of ventilation 29,31,38.  In addition, the adipose tissue, initially believed to be 
inert, is now known to be the site of release of numerous pro-inflammatory and anti-
inflammatory cytokines 28. Therefore, leptin is now considered to play a role in the 
body’s host inflammatory response, both in relationship to adiposity and other 
inflammatory pathways. 
Given leptin’s involvement with inflammation, a few studies have investigated a 
potential link between leptin and lung function. Studies in animals have suggested that
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 leptin is involved in respiratory control. For example, when comparing mutant LEP mice 
to their wild type counterparts and even before the onset of obesity, the mutant mice have 
increased breathing frequency, minute ventilation and tidal volume, elevated PaCO2 and 
depressed hypercapnic ventilatory response. Chronic leptin administration restores 
breathing rates and improves lung compliance 30,32. However, because leptin 
administration in mice also decreases weight, the improvement of breathing and lung 
compliance cannot be conclusively attributed to leptin therapy and may not simply a 
result of lowered body mass index (BMI). Acute leptin replacement, on the other hand, 
has led to increased baseline ventilation independent of weight gain, and leptin injections 
in rat brain has led to increased pulmonary ventilation and respiratory volume 29. Leptin 
has also been observed to be involved in the regulation of embryonic lung growth and 
maturation 106,117. Specifically, administration of leptin to antenatal mice has led to 
improved lung development in the newborn 117, whereas leptin-deficient mice have been 
observed to have impaired alveolar formation and lower lung volumes at birth 106. 
Additionally, postnatal leptin treatment of these same mice has resulted in increased 
alveolar surface area and lung volume 106. 
Whereas the consensus in animal models is that higher leptin levels are correlated 
with improved respiratory response, human studies yield either null findings or an inverse 
association. Clinical studies have found that leptin is a predictor of lung function in 
asthmatic children 35 and is negatively correlated to lung volumes in patients with chronic 
obstructive pulmonary disease 118 and clinical severity of asthma 119. Van den Borst et al, 
2012 observed no association between FEV1 and serum leptin levels but found that 




women 52. There has also been an observed inverse association between serum leptin 
levels and lung function in an African American population 89 and in a twin population 52. 
Specifically, Hickson et al detected an inverse association between serum leptin levels 
and predicted FEV1 and predicted FVC % independent of adiposity (total body weight, 
waist circumference, and BMI) in an African American population women of a normal 
body weight 89. The explanatory models were also adjusted for age, education, smoking 
status, pack-years of cigarette smoking, respiratory medication use, and menopausal 
status in women.  Sin et al in a large sample (N=2808) also observed and inverse 
association between serum leptin levels and FEV1 and FVC% predicted, independent of 
adipocytes in men but found no such pattern in women 88. However, in a study involving 
prepubertal boys and girls, increased leptin levels were associated with asthma only in 
boys 48. In an Indian population, increased plasma leptin was associated with decreased 
FEV1 but no association was found for FVC.  
Although these studies suggest a role of leptin in lung function, their designs lack the 
appropriate temporal sequence.  The above-mentioned studies are cross-sectional or case-
control studies and either focus on the stage of childhood or well into middle age. The 
current study provided a longitudinal analysis addressing a time-order of exposure to 
leptin with later measurements of lung function, particularly during the transition from 
childhood to adulthood.  
Using data from the Isle of Wight Birth Cohort, we tested the association of leptin at 
ages 10 and 18 years with FVC, FEV1, and FEV1/FVC at ages 10 and 18 years. We tested 






5.2.1 POPULATION CHARACTERISTICS 
A whole population birth cohort was established on the Isle of Wight, UK, in 
1989 to prospectively study the natural history of allergies starting from birth. Ethics 
approvals were obtained from the Isle of Wight Local Research Ethics Committee (now 
the National Research Ethics Service Committee South Central – Southampton B). Of the 
1,536 children born between January 1, 1989, and February 28, 1990, written informed 
consent was obtained from parents to enroll 1,456 newborns. Children were followed up 
at the ages of 1 (n=1,167), 2 (n=1,174), 4 (n=1,218), 10 (n=1,373), and 18 years 
(n=1,313). The IOW birth cohort has been described in detail elsewhere 153. Detailed 
interviews and examinations were completed for each child at each follow-up, including 
BMI. When a visit was not possible, a telephone questionnaire was completed or a postal 
questionnaire was sent. However, blood draw and the spirometric tests required that the 
child visited the David Hide Asthma and Allergy Research Centre. 
 
5.2.2 LEPTIN COLLECTION 
Leptin concentrations were obtained from blood samples collected from at ages 
10 and 18 years. Aliquots of blood serum isolated from the blood samples were used in 
enzyme-linked immunosorbent assays from Biokit, S.A. (Barcelona, Spain). The assays 
were conducted according to the manufacturer’s kit instructions. Each sample, including 
standards and the blank, was assayed in duplicate. Leptin that was collected at age 10 was 
analyzed in two different labs by two different investigators. Adjustments were made for 




Leptin levels that were collected at age 18 were determined by one of the same 
investigator and same laboratory that collected leptin at age 10, providing some 
consistency.  
 
5.2.3 LUNG FUNCTION MEASUREMENTS 
FVC and FEV1 were measured at ages 10 and 18 years.  Lung function testing 
was performed using the Koko spirometry software package on a portable desktop device 
(PDS Instrumentation, Louisville, KY, USA) 154. Tests were performed in accordance 
with American Thoracic Society and European Respiratory Society spirometry guidelines 
175. Children were required to be free from respiratory infection for 14 days and not 
taking systemic oral steroids.  In addition, subjects were asked to abstain from any beta-
agonist medication for at least 6 hours and from caffeine intake for at least 4 hours prior 
to testing. Measurements were made in a standardized manner with the subject standing 
without a nose clip 155. Forced vital capacity (FVC) was recorded in liters as the best of 
three consecutive forced expiratory maneuvers. Participants that exhibited clinical 
symptoms consistent with either current infection or a recent (within two weeks) asthma 
exacerbation, which required antibiotics or oral steroid within the preceding two weeks, 
were rescheduled for spirometry testing.  
 
5.2.4 STATISTICAL ANALYSIS 
 Linear models were used the test the association between leptin and lung function 
(FVC, FEV1, and FEV1/FVC). First, concurrent models tested the association between 




18 years. Second, change in leptin levels from ages 10 to 18 were employed to predict 
lung function at age 18 years (time-delayed model). Since prior findings suggested 
variations of the associations by the sex of the child, boys and girls were analyzed 
separately. In the concurrent models, we controlled for height and BMI at the respective 
ages. In the delayed model, we controlled for height at age 18, change in height between 
ages 10 and 18, and change in standardized BMI from ages 10 to 18.  
 Lastly, we tested the association between change in leptin levels interacting with 
sex and lung function at age 18, stratifying the analysis by categorized BMI levels of low, 
normal, and high.  All analyses were done using SAS 9.4 (Gary, NC).  
 
5.3 RESULTS  
 Of the 1,313 participants who were followed-up at age 18, 132 had data on leptin, 
lung function, BMI, and height at ages 10 and 18 years. There was no statistical 
difference between the cohort that followed up at age 18 and the sample of people that 
were used in this study (Table 5.2). Girls had significantly higher levels of leptin at ages 
10 and 18 years than boys (Table 5.1). Conversely, boys had significantly higher FVC 
and FEV1 at both ages compared to girls. On average, between the ages of 10 and 18 
years, leptin levels in boys increased by 1.3 ng/mL while that in girls increased by 12.9 
ng/mL, this difference in change between the sexes was statistically significant. In some 
boys, leptin levels dropped from ages 10 to 18. When investigating this change in leptin 
levels throughout puberty and the relationship it could have on lung function at age 18, 
we observed that the pattern in boys and girls was markedly different (Figure 5.1). In 




remained low, whereas in girls, FVC and FEV1 at age 18 remained the same across a 
range of levels of change in leptin.  
 Controlling for BMI, concurrent models revealed that in boys, increased leptin 
levels were associated with decreased FVC and FEV1 at age 10 (Table 5.3). A similar 
pattern was observed in girls but only when analyzing the concurrent relationship 
between leptin and FEV1 at age 10 (Table 5.3). No association was found between leptin 
at age 10 and FEV1/FVC at age 10 in either boys or girls. In addition, concurrent models 
at age 18 did not reveal any significant associations with leptin considering any of the 
lung function measurements in boys or girls. This a cross-sectional analysis did not allow 
for an evaluation of the time order between leptin and lung function.  
Given the changes in leptin serum concentrations, to further investigate the time 
order of exposure and effect, we tested whether there was an association between a 
change in leptin levels (from ages 10 and 18) and lung function at age 18. In boys only, 
for every 1 ng/mL increase in the change in leptin from age 10 to 18 years, FVC at age 18 
decreased by 0.016 L. A similar pattern was observed in FEV1 in boys where, for every 1 
ng/mL increase in the change in leptin from ages 10 to 18 years, FEV1 decreased by 
0.014 L. (Table 5.4). No significant associations were detected in girls when testing the 
association between change in leptin levels and lung function measurements at age 18.  
The analysis of an interaction between change in leptin levels and sex with lung 
function at age 18 revealed that in normal BMI only (N=234), for every 1 ng/mL 
increased change in leptin between ages 10 and 18, boys had 0.02 L higher FEV1 at age 






 At age 10, our study shows an association between leptin and lung function that 
exists even after controlling for body mass index (BMI). Both in boys and girls, increased 
leptin levels were associated with decreased lung function. However, we observed 
different patterns of leptin and lung function between boys and girls, both at ages 10 and 
18 years. In girls, the increase in leptin between ages 10 and 18 was significantly higher 
than the increase seen in boys (mean +1.3 in boys versus +12.9 in girls, p-Value: 
<0.0000001).  Conversely, boys had nearly double the increase in FVC (in liters) 
following adolescence than girls (mean +3.0 in boys vs +1.7 in girls, p-Value: 
<0.0000001). In boys only, the greater the increase in leptin between ages 10 and 18, the 
lower FVC and FEV1 at age 18. Therefore, the change in leptin levels during puberty 
(from age 10 to 18) was associated with FVC and FEV1 levels at age 18, controlling for 
BMI and height changes. In those with normal BMI, boys who had a greater change in 
leptin between ages 10 and 18 had 0.02 L higher FEV1 (P-value=0.03) than girls.  
 Of those participants who were followed-up at ages 10 and 18, data on lung 
function measures, height, BMI, and leptin was available in a sample of 307 children. 
There were no statistically significant differences in demographic and personal 
characteristics between the sample population used in the analysis and the entire cohort 
(Table 5.2), minimizing the possibility of selection bias in the study. When considering 
the pubertal period between ages 10 and 18, we saw a significant association between the 
change in leptin-sex interaction and lung function, only in normal weight participants 
(N=234). However, the smaller sample size in the low (N=18) and high (N=47) BMI 




nurses measured lung function, height, and weight, reducing the possibility of 
information bias. There was a possibility of information bias when considering leptin 
samples at age 10 because they were collected by two different investigators in different 
laboratories. However, we standardized these values. In addition, after standardization, 
we also controlled for the lab effect in all our models and found that it is did not have a 
significant effect on our analysis. 
 Since leptin is involved in inflammatory pathways in the body, it would be helpful 
to consider relevant cytokines that could play a role in the association between leptin and 
lung function. It is thought that when leptin binds to the leptin receptor, a down-stream 
JAK2/STAT pathway is activated 134-139,176-179 which results in the release of pro-
inflammatory cytokines, such as Th1, TNF-α, IFN-γ, IL-2, IL-6, IL-12, and IL-10 86. 
Among these cytokines, we had collected IL-10 and IL-12 in our study, and we tested 
their association with FVC, FEV1, and FEV1/FVC at ages 10 and 18 with null results 
(Appendix C and D).  
In other studies, it has been observed that testosterone inhibits the expression of 
leptin in the body while ovarian sex steroids have the opposite effect 55,59,60. This is 
supported by our data that shows significantly higher leptin levels in girls at both ages, as 
well as a significantly higher increase between ages in girls compared the change 
observed in boys (Table 5.1). Since we did not have data on sex steroid levels in our 
participants we used the proxy measure of controlling for pubertal events in our models. 
These pubertal events included ages of onset of breast growth and menarche in girls, age 
of growth spurt in boys, average age of pubertal onset, and duration of onset of pubertal 




by our team 153. We found that none of the pubertal events were significant in any of our 
models.   
 
5.5. CONCLUSION 
 The role of leptin in lung function is still not completely clear and the different 
trends observed in boys and girls has not been explained. Although notable changes occur 
in leptin and lung function level during the transition between childhood to adulthood, 
looking at the onset of pubertal events does not explain the associations observed 
between these two factors. It would be important to explore more direct variables, such as 
sex steroid levels or relevant genes that play a role in sex steroid synthesis. Furthermore, 








Table 5.1 Population characteristics 
 
 Male Female  
 N Mean Median p5, p95 N Mean Median p5, p95 P-value 
Leptin at age 10 (ng/mL) 150 3.19 1.55 0.4, 12.2 246 8.2 4.2 0.6, 29.2 <.0000001 
Leptin at age 18 (ng/mL) 288 3.99 1.22 0.4, 13.1 265 18.9 13.1 2.4, 54.6 <.0000001 
Change in leptin  
between ages 10 and 18 (ng/mL) 
145 1.3 0 -3.9, 10.0 174 12.9 9.3 -4.0, 
44.8 
<.0000001 
Height at age 10 (cm) 488 2.35 2.33 1.8, 2.9 493 2.2 2.2 1.7, 2.8 0.8099200 
Height at age 18 (cm) 395 5.3 5.3 4.2, 6.6 443 4.0 4.0 3.1, 4.8 <.0000001 
Change in height  
between ages 10 and 18 (cm) 
391 38.9 39.0 31.6, 46.5 436 25.7 26.2 15.8, 
33.9 
<.0000001 
Forced vital capacity  
(FVC) at age 10 (L) 
488 2.35 2.33 1.8, 2.9 493 2.2 2.2 1.7, 2.8 <.0000001 
FVC at age 18 (L) 395 5.3 5.3 4.2, 6.6 443 4.0 4.0 3.1, 4.8 <.0000001 
Change in FVC  
between ages 10 and 18 (L) 
326 3.0 3.0 2.1, 3.9 372 1.7 1.7 1.1, 2.4 <.0000001 
Forced expiratory volume in one 
second (FEV1) at age 10 (L) 
488 2.06 2.04 1.6, 2.6 492 2.00 2.00 1.6, 2.5 0.0011217 
FEV1 (L) at age 18 396 4.62 4.55 3.6, 5.6 443 3.47 3.48 2.7, 4.2 <.0000001 
Change in FEV1  
between ages 10 and 18 (L) 
327 2.5 2.5 1.9, 3.2 372 1.5 1.5 0.9, 2.0 <.0000001 
FEV1/FVC at age 10 488 0.88 0.88 0.8, 0.97 492 0.90 0.90 0.8, 0.98 0.0000003 
FEV1/FVC at age 18 396 0.87 0.87 0.7, 0.98 443 0.88 0.88 0.8, 0.98 0.0060977 
Change in FEV1/FVC  
between ages 10 and 18 
327 -0.01 -0.01 -0.01, 0.09 372 -0.02 -0.01 -0.1, 
0.07 
0.2687622 
Standardized BMI at age 10 (kg/m2) 516 -0.2 -0.4 -1.2, 1.6 527 0.19 -0.05 -1.1, 2.4 <.0000001 
Standardized BMI at age 18 (kg/m2) 465 -0.2 -0.3 -1.2, 1.6 499 0.15 -0.08 -1.1, 2.4 0.0000005 
Change in standardized BMI  
between ages 10 and 18 (kg/m2) 








Table 5.2 Population Characteristics in sample and whole cohort at age 18 
 
 Cohort at age 18 follow up Sample used in analysis  
 N Mean Median P5, P95 N Mean Median P5, P95 P-
Value 
Leptin at age 18 (ng/mL) 553 11.12 4.92 0.40, 43.0 317 12.65 6.78 0.40, 
48.96  
0.25 
FVC at age 18 (L) 838 4.61 4.47 3.22, 6.28 307 4.66 4.46 3.34, 6.41 0.44 
FEV1 at age 18 (L) 839 4.01 3.91 2.85, 5.41 308 4.07 3.97 3.01, 5.42 0.25 
FEV1/FVC at age 18 839 0.87 0.88 0.75, 0.98 308 0.88 0.88 0.76, 0.98 0.54 
Standardized BMI at age 18 (kg/m2) 964 5.6E-15 -0.24 -1.15, 2.07 317 0.09 -0.17 -1.03, 2.24 0.21 
Height at age 18 (cm) 994 171.2 171.0 156.5, 
187.0 
317 171.0 171.0 156.0, 
186.0 
0.83 
 N %   N %  P-Value 
Female                                       Male 786 51.17   144 45.4   0.60 





Table 5.3 Concurrent models at age 10 years in girls and boys 
 
Variable Estimate STD P-Value 
FVC at age 10 in BOYS (Liters) 
Leptin at age 10 (ng/mL) -0.016 0.007 0.02 
Standardized BMI at age 10 (kg/m2)  0.077 0.041 0.07 
Height at age 10 (cm) 0.038 0.004 <.0000001 
FEV1 at age 10 in BOYS (Liters) 
Leptin at age 10 (ng/mL) -0.014 0.006 0.03 
Standardized BMI at age 10 (kg/m2)  0.048 0.037 0.20 
Height at age 10 (cm) 0.030 0.003 <.0000001 
FEV1 at age 10 in GIRLS (Liters) 
Leptin at age 10 (ng/mL) -0.005 0.002 0.02 
Standardized BMI at age 10 (kg/m2)  0.050 0.020 0.013 






Table 5.4. Change in leptin levels between ages 10 to 18 predicting FVC and FEV1 at 
age 18 years in girls and boys 
 
Variable Estimate STD P-Value 
FVC at age 18 in BOYS (Liters) 
Change in leptin from ages 10 to 18 
years (ng/mL) 
-0.017 0.0072 0.018 
Change in standardized BMI from 
ages 10 to 18 years (kg/m2)  
0.402 0.095 0.000045 
Change in height from ages 10 to 18 
years (cm) 
-0.025 0.014 0.082 
Height at age 18 (cm) 0.071 0.009 <0.0000001 
FEV1 at age 18 in GIRLS (Liters) 
Change in leptin from ages 10 to 18 
years (ng/mL) 
-0.013 0.0060 0.029 
Change in standardized BMI from 
ages 10 to 18 years (kg/m2)  
0.235 0.079 0.0037 
Change in height from ages 10 to 18 
years (cm) 
-0.021 0.012 0.069 






Table 5.5 Interaction of change in leptin levels between 10 and 18 years with sex 
associated with FEV1 at age 18, stratified by low, normal, and high BMI categories 
 
Variable Estimate STD P-Value 
BMI=low; N=18 
Delta Leptin(ng/mL)1 0.01 0.05 0.83 
Sex (Male vs Female) 1.20 0.40 0.01 
Delta Leptin (ng/mL) * sex (Male vs Female) -0.13 0.09 0.16 
Delta Height2 (cm) -0.04 0.03 0.16 
Height at age 18 (cm) 0.03 0.02 0.17 
BMI=normal; N=234 
Delta Leptin(ng/mL)1 -0.003 0.004 0.35 
Sex (Male vs Female) 0.63 0.10 <0.0000001 
Delta Leptin (ng/mL) * sex (Male vs Female) 0.02 0.009 0.03 
Delta Height2 (cm) -0.009 0.007 0.19 
Height at age 18 (cm) 0.05 0.005 <0.0000001 
BMI=high; N=47 
Delta Leptin(ng/mL)1 -0.005 0.004 0.18 
Sex (Male vs Female) 0.38 0.24 0.13 
Delta Leptin (ng/mL) * sex (Male vs Female) -0.007 0.007 0.30 
Delta Height2 (cm) -0.006 0.01 0.63 
















CONCLUSION AND FINAL REMARKS 
 
 This dissertation contributes to knowledge of the role of leptin in the body’s host 
inflammatory response by showing an association between LEPR SNPs and lung 
function, and presenting a possible mechanism of this association. We found that LEPR 
SNPs were associated with decreased FVC, FEV1 and FEV1/FVC in a repeated 
measurement analysis (SA1). Using data from the F1 generation Isle of Wight birth 
cohort, we then demonstrated a two-stage model of epigenetic analysis (SA2) by first 
identifying methQTLs in the association between LEP SNPs and LEP DNA methylation 
and second, finding an association between an LEP CpG sites (that were identified in 
stage 1) and serum leptin levels.  We replicated the stage 1 findings in the F2 generation 
cohort. Lastly, we found that increases in leptin levels from ages 10 to 18 were associated 
with decreased lung function in boys as girls; and that in those with normal BMI, boys 
who had a greater change in leptin between the ages of 10 and 18 years had a higher 
FEV1 than girls (SA3).  
 
6.1 SUMMARY OF AIM 1 
Our longitudinal analysis of repeated measurements of FVC, FEV1, and 
FEV1/FVC identified one LEPROT and two LEPR SNPs that were associated with lung 




SNPs. To our knowledge, we were the first to explore the longitudinal association 
between LEP SNPs (rs10249476, rs11763517, rs4731429, and rs10954176) and FVC, 
FEV1, FEV1/FVC.  More studies need to be conducted on LEP SNPs (the ones used in 
this study as well as other genetic variations) for comprehensive understanding of the role 
of LEP and LEPR SNPs.  
Regarding LEPR SNPs, the CC genotype of rs6669354 was associated with 
decreased FVC and FEV1 when compared to the AA genotype. Similarly, the AA 
genotype of rs1137101 was associated with decreased FEV1/FVC when compared to the 
GG genotype. Despite leptin and lung function values being significantly different 
between boys and girls, especially the change between ages 10 and 18 years, we did not 
find that sex modified the relationship of these SNPs with lung function. We also did not 
find that the child ever smoking or breastfeeding duration modified the relationship.  
A potential shortcoming in looking at LEPR SNPs is that we cannot known what 
splicing will occur. Of the leptin receptor’s six isoforms, it is the long form for the leptin 
receptor, LEPRb, that circulating leptin binds to which starts the inflammatory pathway 
that can lead to airway obstruction.  Therefore, it may be more useful to investigate the 
leptin receptor protein. In addition, there are other genes that could influence leptin’s 
relationship with lung function.  
 
6.2 SUMMARY OF AIM 2 
 We used the two-stage epigenetic model of analysis to first identify methQTLs 
(specifically LEP SNPs rs11763517 and rs4731429 associated with LEP DNA 




age 18 were associated. We did not find an interaction between maternal smoking during 
pregnancy and LEP SNPs in predicting DNA methylation levels. We successfully 
replicated our methQTL analysis in the F2 population cohort. Specifically, we found that 
in the F1 population, LEP SNP rs4731429 was associated with increased DNA-M at 
cg00666422 and cg00840332 and decreased DNA-M at cg24862443 on the LEP gene; 
rs11763517 was associated with decreased DNA-M at the cg24862443 site. In the F2 
population, rs11760956 (in LD with rs4731429) is associated with increased DNA 
methylation at cg00666422 and cg00840332.   
 Given that the leptin receptor is a requirement for the initiation of inflammatory 
pathways involving leptin, a necessary next step is to further investigate the leptin 
receptor protein as well as LEPR DNA methylation. It would also be interesting to see 
how the leptin receptor and leptin proteins and genes interact with each other in these 
associations.  
  
6.3 SUMMARY OF AIM 3 
 We found that in both boys and girls, the higher the increase in leptin serum 
concentrations between ages 10 and 18, the lower the lung function measurements. In 
those with normal BMI, for every one ng/mL increase in the change in leptin between 
ages 10 and 18, boys had 0.02 L higher FEV1 than girls. Investigating at both ages 10 and 
18, we did not find any associations between cytokines IL-10 and IL-12 with FVC, FEV1, 
or FEV1/FVC. Regarding pulmonary function, we observed that the increase in FVC and 
FEV1 between ages 10 and 18 in boys nearly doubled compared to the increase in girls. 




observed in boys. These differential changes that occur during the pubertal transition 
suggest that puberty may play a role in this difference between the sexes. Furthermore, 
testosterone is known to suppress leptin while ovarian sex hormones are associated with 
increased leptin. However, when testing markers of puberty onset in our dataset (such as 
the age of onset of menarche or the age of onset of growth spurt), we found no 
associations in our models. We were not able to explain this difference between boys and 
girls. Improved markers for pubertal changes, such as levels of sex steroid hormones, or 
additional genetic markers may provide further insights.  
 We successfully demonstrated an association between leptin protein and lung 
function measurements that existed even after adjusting for BMI. However, although 
leptin is associated with obesity, BMI is not the most accurate approximation of 
adiposity.  Nevertheless, future studies should investigate whether co-variation of BMI 
and leptin may be improved when using other variables for adiposity. In addition, we 
only had two cytokines (IL-10 and IL-12) in our dataset that were relevant to leptin and 
the body’s immune response. When looking at the relationship between leptin and lung 
function, the association could be mediated by other cytokines that are more directly 
related to this inflammatory process. A few relevant cytokines to be considered are IL-1β, 
IL-6, IL-8, IL-12, TNF-α, and TNF-γ. Lastly, when looking at the protein-to-lung 
function association, the leptin receptor protein must also be included. There could be a 
more direct relationship between concentrations of LEPRb (the long isoform of the leptin 






6.4 FINAL REMARKS 
Leptin clearly plays a role in inflammation and is associated with lung function, 
but this association still needs to be better explored. Our longitudinal analysis of SNPs 
and lung function revealed that LEPR SNPs (but not LEP SNPs) were associated with 
FVC, FEV1, and FEV1/FVC.  Therefore, the leptin receptor may play a more prominent 
role in lung function than leptin and more studies should consider the leptin receptor 
protein when investigating leptin’s relationship with lung function and obstructive 
pulmonary diseases. When possible, studies should specifically look at the longform of 
the leptin receptor (LEPRb) because it is that isoform that, when bound to the leptin 
protein, is involved with the JAK/STAT pathway. 
A weakness of our study could be that we only had data on four LEP SNPs, 
although these SNPs did span the length of the leptin gene. In our data CpG sites on the 
leptin gene were mostly located in the promoter region, with only one in the 3’ UTR 
region and none in the coding or intron regions. It might be illuminating to perform the 2-
stage analysis demonstrated in SA2 with different LEP SNPs and CpG sites. We also did 
not have data on cytokines that were more closely linked to leptin or lung function, which 
prevented us from doing a path analysis in SA3 (testing the theoretical path of protein 
leptincytokinelung function measurement). Lastly, there was a possibility of 
information bias in the collection of leptin levels at age 10 since the values were collected 
by two different investigators in two different labs. However, we corrected for this by 
standardizing the leptin values and controlling for the different labs in the models.  
A strength of this dissertation is that in all three specific aims, the possibility of 




methylation data was superior to other methods, and we successfully replicated our 
methQTL analysis of the F1 population in the F2 generation cohort (SA2). We found an 
association between LEPR SNPs and lung function and presented a potential mechanism 
for this association via LEP DNA methylation and serum leptin protein.   
A consistent theme throughout this dissertation was the importance of considering 
boys and girls separately when looking at leptin and lung function (and by extension, 
other pulmonary disorders). Although we could not explain the differences between boys 
and girls in leptin and lung function levels at the genetic level, we did see a difference 
between boys and girls when investigating the interaction effect of change in leptin and 
sex on lung function at age 18. More studies need to investigate the mechanism behind 
these observed changes so that potential clinical attempts to treat suboptimal lung 
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ASSOCIATION OF LEP, LEPR, AND LEPROT SNPS 





BMI age 10  
(P-value) 
BMI age 18   
(P-value) 
LEPrs4731429 0.0102 0.0892 
LEPrs10249476 0.0166 0.3117 
LEPrs10954176 0.4254 0.3054 
LEPrs11763517 0.0327 0.7317 
LEPRrs3806318 0.5306 0.5477 
LEPROTrs17412175 0.3387 0.3867 
LEPRrs7526141 0.3480 0.9443 
LEPRrs1137101 0.6604 0.8446 
LEPROTrs9436740 0.0518 0.2136 
LEPROTrs9436301 0.2881 0.1414 
LEPROTrs6669354 0.3264 0.2773 
LEPRrs12059300 0.4537 0.9881 
LEPRrs3762274 0.6499 0.1330 

























BOYS: SPEARMAN CORRELATIONS OF LEPTIN AND LUNG FUNCTION VALUES AT  
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GIRLS: SPEARMAN CORRELATIONS OF LEPTIN AND LUNG FUNCTION VALUES AT  
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